Information on EC 3.4.23.46 - memapsin 2

New: Word Map on EC 3.4.23.46
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY
3.4.23.46
-
RECOMMENDED NAME
GeneOntology No.
memapsin 2
-
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
broad endopeptidase specificity. Cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
show the reaction diagram
-
-
-
-
broad endopeptidase specificity. Cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
show the reaction diagram
enzyme is an aspartic protease but is atypical in containing a C-terminal membrane-spanning domain
-
broad endopeptidase specificity. Cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
show the reaction diagram
memapsin 1 and 2 have overlapping yet distinct sequence preference; suggested to be the major 'beta-secretase' responsible for the cleavage of the beta-amyloid precursor protein to form the amyloidogenic beta-peptide that is implicated in the pathology of Alzheimer's disease
-
broad endopeptidase specificity. Cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
show the reaction diagram
mechanism for enzyme regulation
-
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
alpha-secretase
-
-
alpha-secretase
-
-
amyloid precursor protein secretase
-
-
-
-
APP secretase
-
-
-
-
Asec-1A
-
-
aspartic protease BACE
-
-
-
-
aspartic protease BACE1
-
-
-
-
Aspartic proteinase
-
aspartic proteinase BACE1
-
-
-
-
BACE
-
-
BACE 1
-
-
BACE I
-
-
BACE-1
-
-
BACE-1
-
-
BACE-2
-
-
BACE1
Mus musculus BalbC
-
-
BACE1/beta-secretase
-
-
beta protein amyloidogenase
-
-
-
-
beta-amyloid cleaving enzyme
-
-
beta-amyloid cleaving enzyme 1
-
-
beta-amyloid precursor protein cleaving enzyme
-
-
beta-amyloid protein precursor secretase
-
-
-
-
beta-amyloid-cleaving enzyme
-
-
beta-amyloid-converting enzyme-1
-
-
beta-APP cleaving enzyme 1
-
-
beta-secretase
-
-
-
-
beta-secretase
-
-
beta-secretase
Mus musculus BalbC
-
-
beta-secretase
-
-
beta-secretase enzyme 1
-
-
beta-secretase-1
-
-
beta-secretase-1
-
-
beta-secretase-1
-
-
beta-site Alzheimer's amyloid precursor protein cleaving enzyme 1 (BACE1)
-
-
-
-
beta-site amyloid cleaving enzyme
-
-
beta-site amyloid precursor protein cleaving enzyme
-
-
beta-site amyloid precursor protein cleaving enzyme
-
beta-site amyloid precursor protein cleaving enzyme
-
-
beta-site amyloid precursor protein cleaving enzyme 1
-
-
beta-site amyloid precursor protein cleaving enzyme-1
-
-
beta-site amyloid precursor protein-cleaving enzyme
-
-
beta-site amyloid precursor protein-cleaving enzyme 1
-
-
beta-site APP (amyloid precursor protein) cleaving enzyme
-
beta-site APP cleaving enzyme
-
-
beta-site APP cleaving enzyme
-
beta-site APP cleaving enzyme
-
-
beta-site APP cleaving enzyme 1
-
-
beta-site APP cleaving enzyme 1
-
beta-site APP cleaving enzyme 1
-
-
beta-site APP-cleaving enzyme 1
-
-
-
-
beta-site APP-cleaving enzyme 1
-
-
beta-site APP-cleaving enzyme 1
-
D-aspartyl-beta-amyloid secretase
-
-
-
-
gamma-secretase
-
-
gamma-secretase
-
-
gamma-secretase
-
gamma-secretase is composed of four proteins: presenilin, nicastrin, aph1, and pen2
memapsin 1
-
-
-
-
memapsin 2
-
memapsin 2
-
memapsin2
-
-
membrane-bound aspartic protease
-
-
-
-
NACE1
-
-
presenilin 1
-
catalytic subunit ofgamma-secretase
presenilin-1
-
catalytic component of the multisubunit gamma-secretase complex
presenilin-2
-
catalytic component of the multisubunit gamma-secretase complex
protease Asp2
-
-
-
-
proteinase BACE1
-
-
-
-
CAS REGISTRY NUMBER
COMMENTARY
158736-49-3
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
; sporadic Alzheimer's disease patients
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
; London APP transgenic mouse model of Alzheimer's disease that expresses human amyloid precursor protein containing the wild-type beta-secretase site
-
-
Manually annotated by BRENDA team
BACE1-null and wild-type mice at the ages of 2 and 5 months
SwissProt
Manually annotated by BRENDA team
BalbC mice
SwissProt
Manually annotated by BRENDA team
female ICR mice, ovariectomized or sham-operated, treated with or without daily restraint stress conditions for 6 h per day over 3 weeks
SwissProt
Manually annotated by BRENDA team
transgenic mice strain Tg2576
SwissProt
Manually annotated by BRENDA team
Mus musculus BalbC
BalbC mice
SwissProt
Manually annotated by BRENDA team
var. acuta
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
BACE1 heterozygous deletion rescues conditioned taste aversion memory deficits in 5XFAD mice
metabolism
-
BACE1 is responsible for the first step in the production of the beta-amyloid protein of Alzheimer's disease
physiological function
-
BACE1 is a key protein in the pathogenesis of Alzheimer's disease
physiological function
-
beta-secretase plays a role in neurogenesis
physiological function
-
BACE1 is involved in regulating ectodomain shedding, maturation and trafficking of the amyloid precursor protein family of proteins. BACE1 expression regulates the levels and species of full-length amyloid precursor-like protein 1, amyloid precursor protein, and amyloid precursor-like protein 2, of their shed ectodomains, and of their membrane-bound C-terminal fragments
physiological function
-
BACE1 is the principle beta-secretase responsible for the production of beta-amyloid in the brain
physiological function
-
gamma-secretase (regulated intramembrane proteolysis signaling) plays an important role in the restoration or collapse of axons in the white matter after hemisection of the spinal cord
physiological function
-
BACE1 is the rate-limiting enzyme for production of beta-amyloid peptides, which are proposed to drive the pathological changes found in Alzheimer's disease
physiological function
-
BACE1 knock-out and wild-type nerves degenerate at a similar rate after axotomy and to a similar extent in the experimental neuropathies produced by administration of paclitaxel and acrylamide. BACE1 knock-out mice have markedly enhanced clearance of axonal and myelin debris from degenerated fibers, accelerated axonal regeneration, and earlier reinnervation of neuromuscular junctions, compared with littermate controls
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl) + H2O
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)
show the reaction diagram
-
i.e. FS-2, cleavage occurs at Leu-Asp bond
-
?
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl) + H2O
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)
show the reaction diagram
-
MCA, cleavage product measured by fluorescence assay, significant increases in beta-secretase activity to varying degrees in Alzheimer disease cases identified, increase not immediately correlated with levels of BACE1, differences between BACE1 and BACE2 analyzed
-
?
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)-Arg-Arg-NH2 + H2O
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)-Arg-Arg-NH2
show the reaction diagram
-
synthesis, structure and potencies of beta-secretase BACE1 inhibitors optimized, effects of P4 modification on BACE1 inhibitory activity analyzed
-
?
(7-methoxycoumarin-4-yl)-acetyl-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys-(2,4-dinitrophenyl)-Arg-Arg-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-L-Ser-L-Glu-L-Val-L-Asn-L-Leu-L-Asp-L-Ala-L-Glu-L-Phe-L-Lys-dinitrophenyl + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(Lys-2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-(Lys-2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-SEVNLDAEFRK-(2,4-dinitrophenyl)-RR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-yl-acetyl-SEVNLDAEFR-(2,4-dinitrophenyl)K-RR + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-SEVNLDAEFR-Dpa + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-SEVNLDAEFR-Dpa + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid -like PROTEIN 2 + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
-
BACE1 and the amyloid beta-precursor protein processing pathway are critical for cognitive, emotional and synaptic functions
-
-
?
amyloid pbeta A4 protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
i.e. APP, cleavage occurs between VKM-DA
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
first step in generation of the Abeta peptide is the cleavage of amyloid precursor protein by BACE1. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. BACE1 provides a link between metal homoeostasis and oxidative stress in Alzheimer disease
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
amyloid precursor protein is cleaved at the N-terminus of Abeta by beta-secretase yielding a slightly shorter soluble APPbeta fragment and a slightly longer CTFbeta fragment (also termed C99)
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
BACE1 cleaves amyloid precursor protein at the beta-site
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
BACE1 cleaves APP at the N-terminal end of the Abeta sequence, producing a 14000 Da C-terminal fragment beta or C99
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
beta-secretase cleavage produces s-amyloid precursor protein-beta and the beta-C-terminal fragment C99. ATXN1 loss of function potentiates BACE1 cleavage of amyloid precursor protein
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
cleavage by beta-secretase at the N-terminus of the Abeta domain produces a fragment known as soluble beta-amyloid precursor protein and the remaining cell membrane spanning fragment of amyloid precursor protein (C99)
-
?
amyloid precursor protein + H2O
amyloid protein 1-42 + ?
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
amyloid beta protein 40 + amyloid beta protein 42
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
beta-amyloid peptide 40 + beta-amyloid peptide 42
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment + soluble N-terminal fragment APPbeta
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment C99 of amyloid precursor protein + ?
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
neurotrophic soluble amyloid precursor protein + ?
show the reaction diagram
-
-
-
?
amyloid precursor protein-DELTANL + H2O
?
show the reaction diagram
-
the Swedish familial mutation in APP (DELTANL) enhances beta-secretase cleavage
-
-
?
amyloid-beta precursor protein + H2O
amyloid-beta protein 40 + amyloid-beta protein 42
show the reaction diagram
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
-
beta-secretase first cleaves the ectodomain of amyloid-beta precursor protein to generate a membrane-bound fragment
-
?
amyloid-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
show the reaction diagram
-
i.e. FS-1, cleavage occurs at Leu-Asp bond
-
?
Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
basigin + H2O
?
show the reaction diagram
-
-
-
-
?
beta subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
the loss of Niemann-Pick type C1 increases beta-secretase cleavage of beta-amyloid precursor protein
-
?
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein APP + H2O
beta-amyloid protein + beta-amyloid precursor protein pre-peptide
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein APP + H2O
beta-amyloid protein + beta-amyloid precursor protein pre-peptide
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein APP + H2O
beta-amyloid protein + beta-amyloid precursor protein pre-peptide
show the reaction diagram
-
-
-
?
beta-secretase 1 + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
substrate cleavage investigated, cleavage products beta2-CTFbeta and beta2-ICD characterized, multiple roles in regulating neuronal function through regulating of neuronal BACE1 substrate proteins discussed
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
substrate cleavage investigated, cleavage products beta2-CTFbeta and beta2-ICD characterized, multiple roles in regulating neuronal function through regulating of neuronal BACE1 substrate proteins discussed
-
-
?
biotin-KTEEISEVNFEVEFR + H2O
biotin-KTEEISEVNF + EVEFR
show the reaction diagram
-
-
-
?
BMP and activin membrane-bound inhibitor homolog + H2O
?
show the reaction diagram
-
-
-
-
?
cache domain containing 1 + H2O
?
show the reaction diagram
-
-
-
-
?
carboxypeptidase D + H2O
?
show the reaction diagram
-
-
-
-
?
casein-FITC + H2O
?
show the reaction diagram
-
-
-
-
?
cation-independent mannose-6-phosphate receptor + H2O
?
show the reaction diagram
-
-
-
-
?
CD166 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD276 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD44 + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate proteoglycan 4 + H2O
?
show the reaction diagram
-
-
-
-
?
contactin-1 + H2O
?
show the reaction diagram
-
-
-
-
?
cysteine-rich motor neuron 1 protein + H2O
?
show the reaction diagram
-
-
-
-
?
DABCYL-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-EDANS + H2O
?
show the reaction diagram
-
-
-
-
?
desmoglein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
disintegrin and metalloproteinase domain-containing protein 10 + H2O
?
show the reaction diagram
-
-
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
EEISEVKMDAEFRG + H2O
EEISEVKM + DAEFRG
show the reaction diagram
-
-
-
?
EEISEVNLDAEFRG + H2O
EEISEVNL + DAEFRG
show the reaction diagram
-
-
-
?
ephrin type-A receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 4 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 7 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin-A5 + H2O
?
show the reaction diagram
-
-
-
-
?
ErbB4 + H2O
?
show the reaction diagram
-
-
-
-
?
glypican-3 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi apparatus protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi phosphoprotein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
H-RE(EDANS)EVNLDAEFK(dabcyl)R-OH + H2O
?
show the reaction diagram
-
-
-
-
?
hepatocyte growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
HLA class I histocompatibility antigen (combined) + H2O
?
show the reaction diagram
-
-
-
-
?
HTARWHLRAQDLHERSAAQLSLSS + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor beta chain + H2O
?
show the reaction diagram
-
-
-
-
?
Jagged-1 + H2O
?
show the reaction diagram
-
-
-
-
?
Klotho protein + H2O
?
show the reaction diagram
-
-
-
-
?
Kunitz-type protease inhibitor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 3 + H2O
?
show the reaction diagram
-
-
-
-
?
leucine-rich repeat-containing protein 33 + H2O
?
show the reaction diagram
-
-
-
-
?
low density lipoprotein receptor-related protein + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 11 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
M-2420 peptide + H2O
MCA-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-(N6-dinitrophenylacetyl)Lys-amide
show the reaction diagram
-
cleavage occurs between Leu and Asp
-
?
Mca-SEVNLDAEFRK(2,4-dinitrophenyl)RR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
N-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
neogenin + H2O
?
show the reaction diagram
-
-
-
-
?
netrin receptor UNC5C + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule 1 + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule L1 + H2O
?
show the reaction diagram
-
-
-
-
?
Notch + H2O
Notch intracellular domain + ?
show the reaction diagram
-
-
-
?
Notch protein + H2O
?
show the reaction diagram
-
-
-
-
?
Notch-1 + H2O
?
show the reaction diagram
-
-
-
-
?
oxidized insulin B chain + H2O
?
show the reaction diagram
-
-
-
-
?
panvera peptide + H2O
?
show the reaction diagram
-
-
-
-
?
peptidyl-glycine alpha-amidating monooxygenase + H2O
?
show the reaction diagram
-
-
-
-
?
plexin domain-containing protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
podocalyxin-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
poliovirus receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 21 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 7 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A11 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A5 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A8 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma C3 + H2O
?
show the reaction diagram
-
-
-
-
?
protogenin + H2O
?
show the reaction diagram
-
-
-
-
?
RE(EDANS)EVKMDAEFK(Dabcyl)R-NH2 + H2O
?
show the reaction diagram
-
substrate derived from amyloid beta positions -4 to 4, wild-type, internally fluorescent quenched. Very poor substrate
-
-
?
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2 + H2O
?
show the reaction diagram
-
substrate derived from amyloid beta positions -4 to 4, Swedish mutation, internally fluorescent quenched
-
-
?
receptor protein tyrosine kinase variant EPHB4V1 + H2O
?
show the reaction diagram
-
-
-
-
?
receptor-type tyrosin-protein phosphatase S + H2O
?
show the reaction diagram
-
-
-
-
?
Rh-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-DABCYL + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-Quencher
?
show the reaction diagram
-
FRET oligopeptide substrate
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
FRET-substrate
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
rhodamine-EVNL + DAEFK-quencher
show the reaction diagram
-
-
-
?
roundabout homolog 1 + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 2 + H2O
?
show the reaction diagram
-
-
-
-
?
seizure 6-like protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4B + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4C + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6A + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6D + H2O
?
show the reaction diagram
-
-
-
-
?
SEVKMDAEFR + H2O
SEVKM + DAEFR
show the reaction diagram
-
-
-
?
SEVKMDAEFRHDSGYEK-biotin + H2O
?
show the reaction diagram
-
-
-
-
?
SEVNLDAEFR + H2O
SEVNL + DAEFR
show the reaction diagram
-
-
-
?
SEVNLDAEFRHDSGYEK-biotin + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-1 + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-2 + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin type I + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin-related receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
ST6Gal I + H2O
?
show the reaction diagram
-
i.e. membrane-bound alpha2,6-sialyltransferase, cleavage occurs between Leu37 and Gln38
-
-
?
Swedish mutation of amyloid precursor protein + H2O
fragments of Swedish mutation of amyloid precursor protein
show the reaction diagram
-
-
-
?
Swedish variant of amyloid precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
Swedish variant of amyloid precursor protein + H2O
?
show the reaction diagram
-
i.e. APPSw
-
-
?
syndecan-4 + H2O
?
show the reaction diagram
-
-
-
-
?
T-cell immunomodulatory protein + H2O
?
show the reaction diagram
-
-
-
-
?
toll-like receptor 9 + H2O
?
show the reaction diagram
-
-
-
-
?
trans-Golgi network integral membrane protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
transmembrane protein 132A + H2O
?
show the reaction diagram
-
-
-
-
?
tumor necrosis factor receptor superfamily member 21 + H2O
?
show the reaction diagram
-
-
-
-
?
ubiquitin + H2O
?
show the reaction diagram
-
-
-
-
?
vesicular integral-membrane protein VIP36 + H2O
?
show the reaction diagram
-
-
-
-
?
Z-Val-Asn-Leu-7-amido-4-methylcoumarin + H2O
Z-Val-Asn-Leu + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
membrane-bound prostaglandin E2 synthase-2 + H2O
?
show the reaction diagram
-
BACE-1 is involved in the cleavage of membrane-bound prostaglandin E2 synthase-2 in its N-terminal portion, which, in turn, enhances the generation of prostaglandin E2
-
-
?
additional information
?
-
-
residue specificity of memapsin 1 subsites
-
-
-
additional information
?
-
-
broad endopeptidase specificity, cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
-
-
-
additional information
?
-
-
cleaves at the beta-secretase site of Alzheimer's amyloid precursor protein
-
-
-
additional information
?
-
-
requirements for substrate subsites
-
-
-
additional information
?
-
-
APP mutants with superior cleavage sites
-
-
-
additional information
?
-
-
BACE1 is required for myelination and correct bundling of axons by Schwann cell most likely via processing of type III neuregulin 1
-
-
-
additional information
?
-
-
beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling
-
-
-
additional information
?
-
-
caveolin 1 and flotillin 1 may modulate beta-secretase activity by interacting with BACE1
-
-
-
additional information
?
-
-
identification of autocatalytic cleavage products
-
-
-
additional information
?
-
-
associated role of aspartic proteinase BACE1 in copper homoeostasis shown, link between processing of amyloid precursor protein APP and copper homoeostasis in the brain analyzed
-
-
-
additional information
?
-
BACE1 expression shown to be stimulated by oxidative stress, mechanism of transcriptional induction of BACE1 by oxidative stress discussed as a contribution to production of pathological levels of amyloid beta protein in Alzheimer disease
-
-
-
additional information
?
-
BACE1 function in regulation of myelination and myelin sheath thickness in the central and peripheral nerves determined, abolishment of BACE1 shown to be associated with altered neurological behaviors such as elevated pain sensitivity and reduced grip strength, altered neuregulin-AKT kinase signalling pathway in BACE1-null mice shown
-
-
-
additional information
?
-
influence of combination of ovariectomy and chronic stress on BACE1 activity analyzed
-
-
-
additional information
?
-
-
inhibitors of beta-secretase BACE1 identified and tested
-
-
-
additional information
?
-
-
non-peptidic small molecule inhibitors of beta-secretase BACE1 generated, inhibitory activities analyzed by BACE1-FRET assay
-
-
-
additional information
?
-
-
overview about investigations of BACE1 protein levels and beta-secretase activity in control and Alzheimer disease brain under consideration of expression of BACE2 in the human brain
-
-
-
additional information
?
-
properties of memapsin 2 inhibitors analyzed by cellular assay
-
-
-
additional information
?
-
-
properties of memapsin 2 inhibitors analyzed by inhibitory and cellular assays
-
-
-
additional information
?
-
-
report on crystal structure of the catalytically active form of BACE1, novel structural features of the active form of BACE1 determined, mechanism of modulation of BACE1 activity during cellular trafficking shown by crystallization
-
-
-
additional information
?
-
-
report on process of reversible lysine acetylation of BACE1 in the endoplasmic reticulum and Golgi lumen, transient lysine acetylation shown to control both translocation along the secretory pathway and molecular stability of BACE1
-
-
-
additional information
?
-
-
structure and regulatory elements of beta-secretase BACE1 promoter analyzed, comparative model of transcriptional regulation between BACE1 and BACE2 presented
-
-
-
additional information
?
-
-
substrate specificity of BACE1 summarized, identification of different substrates suggests several roles in brain, association of complete abolishment of BACE1 with specific behavioral and physiological alterations discussed, relationships between key risk factors for Alzheimer disease and pathogenic alterations of BACE1 summarized
-
-
-
additional information
?
-
-
synthesis, structure and potencies of beta-secretase BACE1 inhibitors optimized, in vivo enzymatic stability and permeability across the blood-brain barrier of penta-peptidic inhibitors analyzed, stereoview and molecular surface properties shown, reagents and conditions summarized
-
-
-
additional information
?
-
-
BACE 1 does not cleave Z-Val-Lys-Met-7-amido-4-methylcoumarin
-
-
-
additional information
?
-
-
no substrate: RE(Edans)EVKMisoDAEFK(Dabcyl)R-NH2, substrate derived from amyloid beta positions -4 to 4, wild-type, containing isoAsp at position 1, and RE(Edans)EVNLisoDAEFK(Dabcyl)R-NH2, substrate derived from amyloid beta -4 to 4, Swedish mutation, containing isoAsp at position 1
-
-
-
additional information
?
-
-
does not cleave phosphoglucose isomerase
-
-
-
additional information
?
-
Mus musculus BalbC
BACE1 expression shown to be stimulated by oxidative stress, mechanism of transcriptional induction of BACE1 by oxidative stress discussed as a contribution to production of pathological levels of amyloid beta protein in Alzheimer disease
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
amyloid -like PROTEIN 2 + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
-
BACE1 and the amyloid beta-precursor protein processing pathway are critical for cognitive, emotional and synaptic functions
-
-
?
amyloid pbeta A4 protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
-
first step in generation of the Abeta peptide is the cleavage of amyloid precursor protein by BACE1. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. BACE1 provides a link between metal homoeostasis and oxidative stress in Alzheimer disease
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
amyloid precursor protein is cleaved at the N-terminus of Abeta by beta-secretase yielding a slightly shorter soluble APPbeta fragment and a slightly longer CTFbeta fragment (also termed C99)
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
BACE1 cleaves amyloid precursor protein at the beta-site
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
BACE1 cleaves APP at the N-terminal end of the Abeta sequence, producing a 14000 Da C-terminal fragment beta or C99
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
beta-secretase cleavage produces s-amyloid precursor protein-beta and the beta-C-terminal fragment C99. ATXN1 loss of function potentiates BACE1 cleavage of amyloid precursor protein
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
cleavage by beta-secretase at the N-terminus of the Abeta domain produces a fragment known as soluble beta-amyloid precursor protein and the remaining cell membrane spanning fragment of amyloid precursor protein (C99)
-
?
amyloid precursor protein + H2O
amyloid beta protein 40 + amyloid beta protein 42
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
beta-amyloid peptide 40 + beta-amyloid peptide 42
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment + soluble N-terminal fragment APPbeta
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment C99 of amyloid precursor protein + ?
show the reaction diagram
-
-
-
?
amyloid precursor protein + H2O
neurotrophic soluble amyloid precursor protein + ?
show the reaction diagram
-
-
-
?
amyloid precursor protein-DELTANL + H2O
?
show the reaction diagram
-
the Swedish familial mutation in APP (DELTANL) enhances beta-secretase cleavage
-
-
?
amyloid-beta precursor protein + H2O
amyloid-beta protein 40 + amyloid-beta protein 42
show the reaction diagram
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
-
beta-secretase first cleaves the ectodomain of amyloid-beta precursor protein to generate a membrane-bound fragment
-
?
amyloid-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
basigin + H2O
?
show the reaction diagram
-
-
-
-
?
beta subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
-
the loss of Niemann-Pick type C1 increases beta-secretase cleavage of beta-amyloid precursor protein
-
?
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
-
-
-
?
beta-secretase 1 + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
P56818
-
-
-
?
BMP and activin membrane-bound inhibitor homolog + H2O
?
show the reaction diagram
-
-
-
-
?
cache domain containing 1 + H2O
?
show the reaction diagram
-
-
-
-
?
carboxypeptidase D + H2O
?
show the reaction diagram
-
-
-
-
?
cation-independent mannose-6-phosphate receptor + H2O
?
show the reaction diagram
-
-
-
-
?
CD166 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD276 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD44 + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate proteoglycan 4 + H2O
?
show the reaction diagram
-
-
-
-
?
contactin-1 + H2O
?
show the reaction diagram
-
-
-
-
?
cysteine-rich motor neuron 1 protein + H2O
?
show the reaction diagram
-
-
-
-
?
desmoglein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
disintegrin and metalloproteinase domain-containing protein 10 + H2O
?
show the reaction diagram
-
-
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 4 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 7 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin-A5 + H2O
?
show the reaction diagram
-
-
-
-
?
ErbB4 + H2O
?
show the reaction diagram
-
-
-
-
?
glypican-3 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi apparatus protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi phosphoprotein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
hepatocyte growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
HLA class I histocompatibility antigen (combined) + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor beta chain + H2O
?
show the reaction diagram
-
-
-
-
?
Jagged-1 + H2O
?
show the reaction diagram
-
-
-
-
?
Klotho protein + H2O
?
show the reaction diagram
-
-
-
-
?
Kunitz-type protease inhibitor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 3 + H2O
?
show the reaction diagram
-
-
-
-
?
leucine-rich repeat-containing protein 33 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 11 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
N-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
neogenin + H2O
?
show the reaction diagram
-
-
-
-
?
netrin receptor UNC5C + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule 1 + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule L1 + H2O
?
show the reaction diagram
-
-
-
-
?
Notch + H2O
Notch intracellular domain + ?
show the reaction diagram
-
-
-
?
Notch protein + H2O
?
show the reaction diagram
-
-
-
-
?
Notch-1 + H2O
?
show the reaction diagram
-
-
-
-
?
peptidyl-glycine alpha-amidating monooxygenase + H2O
?
show the reaction diagram
-
-
-
-
?
plexin domain-containing protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
podocalyxin-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
poliovirus receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 21 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 7 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A11 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A5 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A8 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma C3 + H2O
?
show the reaction diagram
-
-
-
-
?
protogenin + H2O
?
show the reaction diagram
-
-
-
-
?
receptor protein tyrosine kinase variant EPHB4V1 + H2O
?
show the reaction diagram
-
-
-
-
?
receptor-type tyrosin-protein phosphatase S + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 1 + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 2 + H2O
?
show the reaction diagram
-
-
-
-
?
seizure 6-like protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4B + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4C + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6A + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6D + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-1 + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-2 + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin type I + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin-related receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
Swedish mutation of amyloid precursor protein + H2O
fragments of Swedish mutation of amyloid precursor protein
show the reaction diagram
-
-
-
?
syndecan-4 + H2O
?
show the reaction diagram
-
-
-
-
?
T-cell immunomodulatory protein + H2O
?
show the reaction diagram
-
-
-
-
?
toll-like receptor 9 + H2O
?
show the reaction diagram
-
-
-
-
?
trans-Golgi network integral membrane protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
transmembrane protein 132A + H2O
?
show the reaction diagram
-
-
-
-
?
tumor necrosis factor receptor superfamily member 21 + H2O
?
show the reaction diagram
-
-
-
-
?
vesicular integral-membrane protein VIP36 + H2O
?
show the reaction diagram
-
-
-
-
?
membrane-bound prostaglandin E2 synthase-2 + H2O
?
show the reaction diagram
-
BACE-1 is involved in the cleavage of membrane-bound prostaglandin E2 synthase-2 in its N-terminal portion, which, in turn, enhances the generation of prostaglandin E2
-
-
?
additional information
?
-
-
broad endopeptidase specificity, cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
-
-
-
additional information
?
-
-
cleaves at the beta-secretase site of Alzheimer's amyloid precursor protein
-
-
-
additional information
?
-
-
BACE1 is required for myelination and correct bundling of axons by Schwann cell most likely via processing of type III neuregulin 1
-
-
-
additional information
?
-
-
beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling
-
-
-
additional information
?
-
-
caveolin 1 and flotillin 1 may modulate beta-secretase activity by interacting with BACE1
-
-
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Cu
-
BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper
Cu2+
-
involvement of aspartic proteinase BACE1 in copper homoeostasis shown, key role of the central of three cysteines (amino acid 482 in 501-amino-acid isoform of BACE1) in metal binding indicated
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(+)-byakangelicin
-
-
(+)-byakangelicol
-
-
(+)-oxypeucedanin
-
-
(-)-gallocatechin gallate
-
less potent inhibitor
(13S)-15-amino-10,13-dicyclohexyl-19-fluoro-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(13S)-15-amino-10,13-dicyclohexyl-19-methoxy-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(13S)-15-amino-10,13-dicyclohexyl-2-oxa-10,14,16,19-tetraazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(14S)-16-amino-10,14-dicyclohexyl-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
potent inhibitor
(14S)-16-amino-10-cyclohexyl-14-(propan-2-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(14S)-16-amino-14-(propan-2-yl)-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(14S)-16-amino-14-cyclohexyl-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(15R)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
-
(15S)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
-
(1R,3S)-3-[(1S)-1-(acetylamino)-2-methylpropyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[(1S)-1-(acetylamino)-3-methylbutyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
11% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)butyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
15% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)ethyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
8% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)propyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
17% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)-3-methylbutyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
42% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)butyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
80% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)cyclopentyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[1-(acetylamino)ethyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
14% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)propyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
24% inhibition at 0.01 mM
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopiperidin-1-yl)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopyrrolidin-1-yl)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(propanoylamino)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-[methyl(propanoyl)amino]propan-2-yl]cyclohexanecarboxamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[(1-benzylpiperidin-4-yl)amino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)-amino]-N'-[(R)-1-(4-fluorophenyl)ethyl]isophthalamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
dual inhibitor of both beta-secretase and acetylcholinesterase, good inhibitory effects on amyloid beta production of amyloid precursor protein transfected HEK293 cells
(1S,2R)-N-{1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl}-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
dual inhibitor of both beta-secretase and acetylcholinesterase. Intracerebroventricular injection of into amyloid precursor protein transgenic mice causes a 29% reduction of amyloid beta1-40 production
(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]butanamide
-
56fold selectivity for beta-secretase over cathepsin D
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide
-
-
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]-4-hydroxy-2-methylbutanamide
-
-
(2R,4S,5S)-N-benzyl-4-hydroxy-2,7-dimethyl-5-[(N-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-seryl)amino]octanamide
-
16.45% inhibition at 0.01 mg/ml
(2R,4S,5S)-N-benzyl-4-hydroxy-5-([N-[(4-methoxyphenyl)acetyl]-L-seryl]amino)-2,7-dimethyloctanamide
-
25.09% inhibition at 0.01 mg/ml
(2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide
-
crystallization data, EC50 value for HEK293 cells 10 nM
(2S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R)-5-(propylsulfonyl)pyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide
-
EC50 value for HEK293 cells 5 nM, shows apical to basolateral permeability of <15 nm/s in the bi-directional Caco-2 model
(2S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R)-5-(propylsulfonyl)pyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide
-
decreases amyloid beta1-40 in wild-type mice and has excellent blood/brain barrier penetration in the absence of P-glycoprotein, P-glycoprotein is the main factor limiting efficacy of this compound
(2S,5S,8S,11S,14S)-14-amino-5-benzyl-8-(cyclohexylmethyl)-16-(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-2-hydroxy-11-(1-methylethyl)-4,7,10,13,16-pentaoxo-N-[3-(2H-tetrazol-5-yl)phenyl]-3,6,9,12-tetraazahexadecan-1-amide
-
i.e. KMI-574, 100% and 97% inhibition at 2 microM and 0.2 microM, respectively, 84% inhibition of beta-secretase BACE1 in cultured cell-based assay at 100 microM
(3S,14R,16S)-16-[(1R)-1-hydroxy-2-([3-(1-methylethyl)benzyl]amino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
-
60fold preference for beta-secretase over cathepsin D
(3S,14R,16S)-16-[(1R)-1-hydroxy-2-([3-(1-methylethyl)benzyl]amino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
-
inhibition of beta-secretase in the brain of amyloid precursor protein 51/16 transgenic mice after intravenous application
(3S,14R,16S)-16-[(1S)-2-[[(1R)-3,3-dimethyl-7-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
-
inhibitory similarly to beta-sectretase and cathepsin D
(3S,14R,16S)-16-[(1S)-2-[[(1R)-3,3-dimethyl-7-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
-
inhibition of beta-secretase in the brain of amyloid precursor protein 51/16 transgenic mice after oral application
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(2-oxopyrrolidin-1-yl)-11,16-dioxa-3-azatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(methoxymethyl)-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]ethyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([2-[3-(propan-2-yl)phenyl]propan-2-yl]amino)ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11-oxa-3,16,18-triazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2,2,2-trifluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-fluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-methoxyethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclobutyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclopentyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(5S)-2-amino-5-(2',4'-difluorobiphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
5fold selectivity for BACE2 over BACE1, 27fold selectivity for BACE2 over cathepsin D
(5S)-2-amino-5-[3-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
aminohydantoin inhibitor, EC50 value in ELISA-assay 20 nM, and demonstrates more than 100fold selectivity for the other structurally related aspartyl proteases BACE2, cathepsinD, renin, and pepsin
(5S)-2-amino-5-[3-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
aminohydantoin inhibitor, EC50 value in ELISA-assay 20 nM, and demonstrates more than 100fold selectivity for the other structurally related aspartyl proteases BACE2, cathepsinD, renin, and pepsin. Acute oral administration at 100 mg/kg results in a 69% reduction of plasma amyloid beta40 at 8 h in a Tg2576 mouse
(6R)-2,6-anhydro-5-O-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-[2-[(2R)-2-hydroxypropyl]-7-methoxy-5-methyl-4-oxo-4H-chromen-8-yl]-L-glucitol
-
inhibitor isolated from Aloe vera and Aloe nobilis. Inhibition of amyloid beta1-42 production by 7.4% in B103 neuroblastoma cells at 30 ppm
(6R)-2,6-anhydro-6-[7-methoxy-5-methyl-4-oxo-2-[(1E)-prop-1-en-1-yl]-4H-chromen-8-yl]-L-glucitol
-
inhibitor isolated from Aloe vera and Aloe nobilis. Inhibition of amyloid beta1-42 production by 12.3% in B103 neuroblastoma cells at 30 ppm
(7S,12Z)-N-[(2S,4R)-2-hydroxy-4-methyl-5-[[(1S)-2-methyl-1-(phenylcarbamoyl)propyl]amino]-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadec-12-ene-7-carboxamide
-
-
(R)-3-(2-amino-6-(3-chloropyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 80 nM
(R)-3-(2-amino-6-(3-methylpyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 35 nM
1,1'-piperazine-1,4-diylbis[3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol]
-
inhibitor identified by in silico mulit-filter approaches. Calculated binding free energy of R,S-isomer -48 kcal/mol
1,1'-piperazine-1,4-diylbis[3-(9H-carbazol-9-yl)propan-2-ol]
-
inhibitor identified by in silico mulit-filter approaches. Calculated binding free energy of S,R-isomer -48.2 kcal/mol
1,3-bis(3,5-bis(trifluoromethyl)phenyl)urea
-
100% inhibition at 100 nM, 15% inhibition at 10 nM
1,5-anhydro-1-[7-hydroxy-2-[(2S)-2-hydroxypropyl]-5-methyl-4-oxo-4H-chromen-8-yl]hexitol
-
37.2% inhibition at 0.1 mM
1,5-anhydro-1-[7-hydroxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]-2-O-[(E)-2-(4-hydroxyphenyl)ethenyl]hexitol
-
39.5% inhibition at 0.1 mM
1,5-anhydro-1-[7-methoxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
41.0% inhibition at 0.1 mM
1,5-anhydro-2-O-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1-[7-hydroxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
36.4% inhibition at 0.1 mM
1,5-anhydro-2-O-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1-[7-methoxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
48.7% inhibition at 0.1 mM
1-(2-chlorobenzyl)-4-(4-(dibenzo[b,d]furan-1-yl)benzyl)-1H-imidazol-2-amine
-
0.005 mM, 37.8% inhibition. Inhibitor is predicted to be able to cross the blood-brain barrier
1-(3,5-bis(trifluoromethyl)-phenyl)-3-(3,5-dimethylphenyl)urea
-
80% inhibition at 100 nM
1-(4-fluorobenzyl)-4-((30,50-dimethoxybiphenyl-4-yl)methyl)-1H-imidazol-2-amine
-
0.005 mM, 40% inhibition. Inhibitor is predicted to be able to cross the blood-brain barrier
1-[ (3-benzoylamino-phenylcarbamoyl)-methyl]-pyridinium chloride
-
51% inhibition at 0.05 mM
1-[(3-benzoylamino-phenylcarbamoyl)-methyl]-3-carbamoyl-pyridiniumchloride
-
54% inhibition at 0.05 mM
1-[(3-benzoylamino-phenylcarbamoyl)-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
55% inhibition at 0.05 mM
1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
61% inhibition at 0.05 mM
1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
42% inhibition at 0.05 mM
1-[(E)-[(4-methylquinazolin-2-yl)amino][(phenylcarbamoyl)amino]methylidene]-3-phenylurea
-
complete inhibition at 0.1 mM
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
78% inhibition at 0.05 mM
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
44% inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylsulfamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
50% inhibition at 0.05 mM
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
-
11-oxo-N-(pyridin-4-yl)-10,11-dihydro-5H-dibenzo[b,e][1,4]-diazepine-3-carboxamide
-
-
16-amino-11-cyclohexyl-2-oxa-11,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-12-one
-
-
1[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
68% inhibition at 0.05 mM
2'-O-coumaroyl-(S)-aloesinol
-
51.9% inhibition at 0.1 mM
2'-O-[p-methoxy-(E)-cinnamoyl]-(S)-aloesinol
-
34.1% inhibition at 0.1 mM
2,3-dihydro-6-methylginkgetin
-
isolated from from Cephalotaxus harringtonia var. fastigiata
2,3-dihydroamentoflavone
-
a 2,3-dihydroamentoflavone from Cycas revoluta
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
-
i.e. norartocarpetin, prenylated flavone from the stem bark of Morus lhou, noncompetitive
2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-6-methoxy-1Hbenzo[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 150fold more effective on BACE1 than BACE2
2-amino-3,4-dihydroquinazoline
-
-
2-amino-3-ethyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(pyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
exhibits modest selectivity (about 8fold) against BACE2
2-amino-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-5-[3-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-phenyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-[2-(propan-2-yl)pyridin-4-yl]-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-[2-methyl-6-(propan-2-yl)pyridin-4-yl]-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
24% inhibition at 0.0125 mM
2-amino-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(1,3-benzodioxol-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,3-dihydro-1-benzofuran-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,6-diethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,6-dimethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2-ethyl-6-methylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
28% inhibition at 0.0125 mM
2-amino-5-(2-ethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3,4-dimethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-butoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-ethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxy-4-methylphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-ethyl-3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-(6-methylbiphenyl-3-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3,4-dimethoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-butoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-chloro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-cyclopentyl-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-propoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-fluoro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(propan-2-yloxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[2-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(2-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(6-fluoropyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(6-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-fluoro-5-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
; aminohydantoin inhibitor, shows comparable activity in a cell-based assay, and demonstrates more than 100fold selectivity for the other structurally related aspartyl proteases BACE2, cathepsinD, renin, and pepsin
2-deoxy-4-O-beta-D-glucopyranuronosyl-6-O-sulfo-2-(sulfoamino)-beta-D-glucopyranose
-
IC50: 0.000053 mg/ml
2-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-2-oxoethyl [(4,6-diphenylpyrimidin-2-yl)sulfanyl]acetate
-
75% inhibition at 0.1 mM
2-[(3-cyano-4,6-diphenylpyridin-2-yl)sulfanyl]-N-(3-nitrophenyl)acetamide
-
complete inhibition at 0.1 mM
2-[(4-methyl-5-[2-[(4-methylphenyl)amino]-2-oxoethyl]-4H-1,2,4-triazol-3-yl)sulfanyl]-N-(4-phenyl-1,3-thiazol-2-yl)acetamide
-
83% inhibition at 0.1 mM
2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]-N-(2-fluorophenyl)acetamide
-
90% inhibition at 0.1 mM
2-[[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]carbamoyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridin-4-yl methanesulfonate
-
i.e. KMI-1036, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]ethanol
-
-
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]ethanol
-
1.7% inhibition at 0.0125 mM
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-5-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]ethanol
-
8.46% inhibition at 0.0125 mM
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-5-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]ethanol
-
5.43% inhibition at 0.0125 mM
2-[[3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl]sulfanyl]-N-(tricyclo[3.3.1.1(3,7)]dec-1-yl)acetamide
-
45% inhibition at 0.1 mM
2-[[3-cyano-6-(4-fluorophenyl)-4-phenylpyridin-2-yl]sulfanyl]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide
-
80% inhibition at 0.1 mM
2-[[4-(4-chlorophenyl)-3-cyano-6-(4-methoxyphenyl)pyridin-2-yl]sulfanyl]-N-(naphthalen-2-yl)-N-phenylacetamide
-
68% inhibition at 0.1 mM
2-[[4-benzyl-5-(1H-indol-3-ylmethyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)ethanone
-
75% inhibition at 0.1 mM
3-(3H-imidazo[4,5-c]pyridin-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(5-(pyridin-4-yl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]-diazepin-11(10H)-one
-
-
3-(6-(2-acetylphenyl)-2-aminoquinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 11 nM
3-(6-fluoro-1H-benzo[d]imidazol-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(benzylsulfanyl)-6-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6,7-dihydro[1,2,4]triazino[5,6-d][3,1]benzoxazepine
-
48% inhibition at 0.1 mM
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(3,3,3-trifluoropropanoyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(methoxyacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-3-ylacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-4-ylacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N2-(3-cyanopropanoyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
3-(butylsulfonyl)-N2-(cyclopropylcarbonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
3-(cyclohexylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(dibutylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(heptan-4-ylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-carbamoyl-1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
44% inhibition at 0.05 mM
3-carbamoyl-1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
69% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
64% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methoxy-phenylsulfamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
34% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
24% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(toluene-4-sulfonylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
4% inhibition at 0.05 mM
3-chloro-N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
-
-
3-phenethylcarbamoyl-1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
58% inhibition at 0.05 mM
3-phenethylcarbamoyl-1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
72% inhibition at 0.05 mM
3-phenethylcarbamoyl-1-[[3-(toluene-4-sulfonylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
36% inhibition at 0.05 mM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.0002 mM, complete inhibition, IC50: 1.2 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
i.e. KMI-684, beta-secretase inhibitors with a hydroxymethylcarbonyl (HMC) isostere, inihbitory activities optimized
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.0002 mM, 98.1% inhibition, IC50: 3.9 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
i.e. KMI-429, beta-secretase inhibitors with a hydroxymethylcarbonyl (HMC) isostere, inihbitory activities optimized
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carbamoylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.0002 mM, 78.1% inhibition
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 87.1% inhibition, IC50: 8.2 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
i.e. KMI-420, beta-secretase inhibitors with a hydroxymethylcarbonyl (HMC) isostere, inihbitory activities optimized
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
-
0.0002 mM, 98.1% inhibition, IC50: 4.8 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
-
i.e. KM-570, beta-secretase inhibitors with a hydroxymethylcarbonyl (HMC) isostere, inihbitory activities optimized
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.0002 mM, 94.2% inhibition, IC50: 6.6 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.0002 mM, 97.2% inhibition, IC50: 6.4 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-(1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl)leucinamide
-
-
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-[1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl]leucinamide
-
-
3-[2-amino-6-(phenylcarbonyl)quinazolin-3(4H)-yl]-N-cyclohexyl-N-methylpropanamide
-
-
3-[5-[(1R)-1-amino-1-methyl-2-phenylethyl]-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide
-
-
3-[[(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)carbonyl]amino]alanyl-L-valyl-N-[(1S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]phenylalaninamide
-
-
3-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]propan-1-ol
-
-
3-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]propan-1-ol
-
47% inhibition at 0.0125 mM
4-(2-amino-6-phenoxyquinazolin-3(4H)-yl)-N,4-dicyclohexyl-N-methylbutanamide
-
-
4-(4-[1-[(6-aminopyridin-2-yl)methyl]-5-(2-chlorophenyl)-1H-pyrrol-2-yl]phenoxy)butanenitrile
-
-
4-(cyclohexylamino)-1-(4-fluorobenzyl)-8-[(2'-methylbiphenyl-4-yl)methyl]-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
4-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]butanamide
-
-
4-bromo-N-[(4-bromophenyl)sulfonyl]-N-[1-(3,4-dichlorobenzyl)-1H-pyrazol-4-yl]benzenesulfonamide
-
50% inhibition at 0.1 mM
4-[1-(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]ethyl]-1-methyl-1H-imidazol-2-amine
-
-
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-(prop-2-en-1-yl)benzamide
-
6.2% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-(propan-2-yl)benzamide
-
6.58% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-butylbenzamide
-
45% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-cyclobutylbenzamide
-
38.4% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-cyclopropylbenzamide
-
10.6% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-ethylbenzamide
-
36% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-propylbenzamide
-
28% inhibition at 0.0125 mM
4-[2-(2-methoxy-5-nitrophenyl)-1-(4-methoxyphenyl)ethyl]-1-methyl-1H-imidazol-2-amine
-
-
4-[4-fluoro-5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
highly active BACE-1 inhibitor
4-[5-methoxy-2-(2-methoxy-5-nitrophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
-
4-[5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
-
4-[8-benzyl-4-(cyclohexylamino)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-1-yl]benzamide
-
-
5-[2-amino-4-(4-methoxy-3-methylphenyl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]biphenyl-2-carbonitrile
-
-
5-[2-amino-4-(biphenyl-3-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]-2-methoxybenzonitrile
-
-
6,7-furano-5,8a-dimethoxy hydrocoumaric acid methyl ester
-
inhibits 57.2% of the BACE1 activity at a concentration of 1 mM
6,7-furano-5-methoxy hydrocoumaric acid
-
-
6,7-furano-5-methoxy hydrocoumaric acid methyl ester
-
-
6,7-furano-5-prenyloxy hydrocoumaric acid
-
-
6,7-furano-5-prenyloxy hydrocoumaric acid methyl ester
-
-
6,7-furano-8,8a-dimethoxy hydrocoumaric acid methyl ester
-
inhibits 48.3% of the BACE1 activity at a concentration of 1 mM
6,7-furano-8-methoxy hydrocoumaric acid
-
-
6,7-furano-8-methoxy hydrocoumaric acid methyl ester
-
inhibits 36.4% of the BACE1 activity at a concentration of 1 mM
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid
-
-
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid methyl ester
-
competitive-type inhibitor
6-([2-(2-chlorophenyl)-5-[4-(1,3-thiazol-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
3.4% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(hexyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
13% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
31% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyrazin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
46.6% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridazin-3-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
10.4% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
6.61% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-3-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
7.1% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-4-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
7.22% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
9.7% inhibition at 0.0125 mM
6-fluoro-2-(3-(7-fluoroimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 200fold more effective on BACE1 than BACE2
6-fluoro-2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo-[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 100fold more effective on BACE1 than BACE2
6-[(2,5-diphenyl-1H-pyrrol-1-yl)methyl]pyridin-2-amine
-
15% inhibition at 0.0125 mM
6-[[2-(2-chlorophenyl)-5-(4-methoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
30% inhibition at 0.0125 mM
6-[[2-(2-chlorophenyl)-5-(4-phenoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
16% inhibition at 0.0125 mM
6-[[2-(2-chlorophenyl)-5-(4-propoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
48% inhibition at 0.0125 mM
6-[[2-(4-butoxyphenyl)-5-(2-chlorophenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
31% inhibition at 0.0125 mM
7-phloroethol
-
significant BACE1 inhibition in a dose-dependent manner
8,8-diphenyl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine
-
-
8-(biphenyl-4-ylmethyl)-4-(cyclohexylamino)-1-(4-fluorobenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
8-C-glucosyl-(R)-aloesol
-
39.2% inhibition at 0.1 mM
8-C-glucosyl-7-methoxy-(R)-aloesol
-
26.8% inhibition at 0.1 mM
8-C-glucosyl-7-O-methylaloediol
-
-
AD115
-
a fragment of Gleevec
AD28
-
a fragment of Gleevec
AD94
-
a fragment of Gleevec
AD95
-
a fragment of Gleevec, strong inhibition
allo-aloeresin D
-
-
aloeresin D
-
71.5% inhibition at 0.1 mM
aloesin
-
37.5% inhibition at 0.1 mM
BACEi-II
-
inhibition may protect neurons from death induced by okadaic acid
benzyl 1-(3-acetoxypropyl)-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(dimethylamino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(isopropyl(methyl)amino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-ethoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4-dimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-methoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(2-morpholino-2-oxoethyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-phenyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-isopropyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [2-([1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]amino)-2-oxo-1-[[(1-propylbutyl)sulfonyl]methyl]ethyl]carbamate
-
-
beta-secretase inhibitor IV
-
complete inhibition at 0.001 mM
beta-secretase inhibitor-II
-
-
C-2'-decoumaroyl-aloeresin G
-
72.0% inhibition at 0.1 mM
CA074Me
-
treatment of London APP transgenic mouse model of Alzheimer's disease that expresses human amyloid precursor protein containing the wild-type beta-secretase site results in substantial improvement in memory deficit assessed by the Morris water maze test. Improved memory function is accompanied by reduced amyloid plaque load, decreased amyloid beta40 and amyloid beta42, and reduced C-terminal beta-secretase fragment derived from amyloid precursor protein by beta-secretase. Inhibitor has no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of amyloid precursor protein
cis-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
-
dieckol
-
significant BACE1 inhibition in a dose-dependent manner
dioxinodehydroeckol
-
significant BACE1 inhibition in a dose-dependent manner
E64d
-
treatment of London APP transgenic mouse model of Alzheimer's disease that expresses human amyloid precursor protein containing the wild-type beta-secretase site results in substantial improvement in memory deficit assessed by the Morris water maze test. Improved memory function is accompanied by reduced amyloid plaque load, decreased amyloid beta40 and amyloid beta42, and reduced C-terminal beta-secretase fragment derived from amyloid precursor protein by beta-secretase. Inhibitor has no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of amyloid precursor protein
eckol
-
significant BACE1 inhibition in a dose-dependent manner
EMD 565788
-
specific BACE1 inhibitor
EVD(statine)VAEF
-
IC50: 0.000651 mM
EVD(statine)VAEF
-
IC50: 0.000603 mM
EVE(statine)VAEF
-
IC50: 0.00045 mM
EVE(statine)VAEF
-
IC50: 0.000452 mM
EVG(statine)VAEF
-
IC50: 0.005319 mM
EVG(statine)VAEF
-
IC50: 0.004673 mM
EVL(statine)VAEF
-
IC50: 0.000265 mM
EVL(statine)VAEF
-
IC50: 0.000251 mM
EVNLAAEF
-
Leu in the transition state isostere, i.e. OM99-2, IC50: 0.0000016 mM
EVNLAAEF
-
Leu in the transition state isostere, i.e. OM99-2, IC50: 0.0000014 mM
EVW(statine)VAEF
-
IC50: 0.00754 mM
EVW(statine)VAEF
-
IC50: 0.0066 mM
EVY(statine)VAEF
-
IC50: 0.000118 mM
EVY(statine)VAEF
-
IC50: 0.000126 mM
Gleevec
-
-
GRL-8234
-
i.e. inhibitor 24, inhibitory and cellular assays described
GRL-8234
i.e. inibitor 24, inhibitory and cellular assays described
heparin
-
leads to increased autocatalytic cleavage of beta-secretase and a subsequent loss of enzyme activity in vitro
Heparin sulfate
-
heparin sulfate analogue derived from porcine mucosal intestinal heparin are effective beta-secretase inhibitors, but have negligible activity as anticoagulants or as inhibitors of other aspartyl proteases structurally related to beta-secretase. The structure of the polysaccharide is important for the interaction with beta-secretase, not simply the level of sulfation or charge
imperatorin
-
-
imperatorin
-
strongest inhibition of BACE1 activity
isoimperatorin
-
-
isopropyl 2-(3-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-methyl-5-((R)-1-phenylethylcarbamoyl)pyridin-1(4H)-yl) acetate
-
-
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenyl butan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
KTEEISEVN(statine)VAEF
-
0.000055 mM
KTEEISEVN(statine)VAEF
-
0.000049 mM
KTEETSEVN(statine)VAEF
-
i.e. P10-P40 StatVal, activity completely abolished using saturating dose of 2.1 microM of the inhibitor, cleavage products of beta-secretase measured by fluoresence assay
kuwanon
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
kuwanon A
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
L-alpha-glutamyl-L-leucyl-N-[(2S,5S,8S,14R)-2-carboxy-5-(carboxymethoxy)-13-hydroxy-11,16-dimethyl-13-oxido-4,7,10-trioxo-1-phenyl-8-(propan-2-yl)-3,6,9-triaza-13-lambda5-phosphaheptadecan-14-yl]-L-alpha-asparagine
-
-
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 99.7% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 98.3% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carbamoylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 29.2% inhibition; 0.002 mM, 62.1% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 83.7% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-([3-(4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]amino)-3-oxopropyl]-L-leucinamide
-
0.002 mM, 74.2% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 92.2% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 94.4% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 91.9% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
-
luteolin
-
isolated from methanolic extracts of Perilla frutescens
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-(statine)-Val-Ala-Glu-Phe-OH
-
-
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe
-
complete inhibition at 0.1 mM
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[statine(3S,4S)]-Val-Ala-Glu-Phe-OH
-
-
memantine
-
-
morusin
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
N'-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-5-methyl-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N'-[(2S,3R)-3-hydroxy-4-[(3-iodobenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N'-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N,N'-bis(3-cyano-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl)-2,2,3,3,4,4,5,5-octafluorohexanediamide
-
87% inhibition at 0.1 mM
N- [N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine tert-butyl ester
-
complete inhibition at 0.1 mM
N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
beta-secretase inhibitor IV, potent inhibitor
N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
beta-secretase inhibitor IV
N-(2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl)methanesulfonamide
-
-
N-(2-methylpropyl)-N2-([17-[(methylsulfonyl)(propyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]icosa-1(19),6(20),7,9,15,17-hexaen-4-yl]methyl)-L-norleucinamide
-
-
N-(4-([4-(cyclohexylamino)-1-(3-fluorophenyl)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-8-yl]methyl)phenyl)acetamide
-
-
N-(4-fluorophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e]-[1,4]diazepine-3-carboxamide
-
-
N-(4-[1-[(6-aminopyridin-2-yl)methyl]-5-(2-chlorophenyl)-1H-pyrrol-2-yl]phenyl)pyrimidin-5-amine
-
9.8% inhibition at 0.0125 mM
N-(5-([6-(4-(N,N-dimethyl)aminophenyl)pyrimidin-4-yl]amino)-2-methylphenyl)-N-methylmethanesulfonamide
-
-
N-(5-[[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidin-4-yl]amino]-2-methylphenyl)-N-methylmethanesulfonamide
-
-
N-(tert-butoxycarbonyl)-L-isoleucyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-isoleucyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-leucyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
54.57% inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-leucyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
0.91% inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-valyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-valyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)valyl-N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(1-methylethyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-L-methioninamide
-
-
N-acetyl-beta-alanyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
N-acetyl-L-alanyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-alaninamide
-
-
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-acetyl-L-valyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-benzyloxycarbonyl-Val-Leu-leucinal
-
-
N-[(1R,2S)-1-benzyl-2-hydroxy-3-[[3-(trifluoromethyl)benzyl]amino]propyl]-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5-(ethylamino)-2-fluorobenzamide
-
-
N-[(1S)-1-[(butylsulfonyl)methyl]-2-([1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]amino)-2-oxoethyl]benzamide
-
-
N-[(1S,2R)-1-benzyl-2-hydroxy-3-[(3-ethoxybenzyl)amino]propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
-
N-[(1S,2R)-1-benzyl-2-hydroxy-3-[(3-ethoxybenzyl)amino]propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
up to 65% reduction of plasma amyloid beta in transgenic mice
N-[(1S,2R,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-1,4-dihydropyridine-2-carboxamide
-
i.e. KMI-1030, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-4H-pyran-2-carboxamide
-
i.e. KMI-1027, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridine-2-carboxamide
-
i.e. KMI-1023, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S,4R)-2-azido-4-((S)-1-benzylcarbamoyl-2-methyl-propylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-(2-methoxy-ethoxy)-butyl]-5-(methanesulfonyl-methylamino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-propyloxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-ethyloxy-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-2-amino-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-allyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-benzyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-cyclopropylmethoxy-1-(3,5-difluorophenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonylmethyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxybutyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenylethyl)-isophthalamide
-
-
N-[(1Z)-amino(butylamino)methylidene]-2-[2-(2-chlorophenyl)-5-(4-propoxyphenyl)-1H-pyrrol-1-yl]acetamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-2-methylbenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-3-hydroxybenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-(trifluoromethyl)benzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methoxybenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methylbenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]pyridine-2-carboxamide
-
-
N-[(2R)-2-amino-1-benzyl-3-fluoropropyl]-2-[[(2-methylcyclopropyl)methyl]amino]-6-[methyl[(1-methylethyl)sulfonyl]amino]pyridine-4-carboxamide
-
-
N-[(2S)-1-([(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]amino)-1-oxo-3-phenylpropan-2-yl]naphthalene-1-carboxamide
-
no inhibition at 0.01 mg/ml
N-[(2S)-1-([(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]amino)-3-(4-nitrophenyl)-1-oxopropan-2-yl]naphthalene-1-carboxamide
-
no inhibition at 0.01 mg/ml
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-1H-imidazole-2-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-4-hydroxypyridine-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-5-methyl-1H-pyrazole-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyrazine-2-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-4-carboxamide
-
-
N-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-3-methylbenzamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(phenylsulfonyl)propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(piperidin-1-ylsulfonyl)propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfamoyl]propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfonyl]propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(phenylsulfonyl)butanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(piperidin-1-ylsulfonyl)butanamide
-
-
N-[(2S,3S)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)amino]benzene-1,3-dicarboxamide
-
-
N-[(2S,3S,5R)-6-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-1-(3,5-difluorophenoxy)-3-hydroxy-5-methoxy-6-oxohexan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
-
N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(2-methylpropyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-5-[methyl(methylsulfonyl)amino]-N'-(1-phenylethyl)benzene-1,3-dicarboxamide
-
-
N-[(3S,6S,13R)-13-[(3-[[(2S)-1-[[(1S)-1-(carboxymethoxy)-2-[[(1S)-1-carboxy-2-phenylethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-3-oxopropyl)(hydroxy)phosphoryl]-3-(carboxymethyl)-2,5-dioxo-1,4-diazacyclotridecan-6-yl]-L-alpha-glutamine
-
-
N-[(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
-
-
N-[(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
-
-
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl-5-methyl(methylsulfonyl)amino]isophthalamide
-
-
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
-
10.48% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-[(2Z)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
37.22% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
-
0.13% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
-
1.47% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-[(2Z)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
22.83% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
-
59.66% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-Nalpha-(tert-butoxycarbonyl)-L-phenylalaninamide
-
22.96% inhibition at 0.01 mg/ml
N-[(5R)-5-amino-5-methyl-4,16-dioxo-14-phenyl-3-oxa-15-azatricyclo[15.3.1.17,11]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide
-
-
N-[(Z)-[(4,6-dimethylpyrimidin-2-yl)amino][(3-nitrophenyl)amino]methylidene]-10H-phenothiazine-10-carboxamide
-
80% inhibition at 0.1 mM
N-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl]-5-methyl-N'-propylbenzene-1,3-dicarboxamide
-
-
N-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N'-propylbenzene-1,3-dicarboxamide
-
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]acetamide
-
80% inhibition at 0.1 mM
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]acetamide
-
-
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-3,4-dichloro-N-phenylbenzamide
-
-
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-4-methoxy-N-phenylbenzamide
-
-
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(2-phenylethyl)benzamide
-
-
N-[5-(2,3-dichlorobenzyl)-1,3-thiazol-2-yl]-4-([[4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]methyl)benzamide
-
78% inhibition at 0.1 mM
N1-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-N3-propylbenzene-1,3,5-tricarboxamide
-
-
N1-[1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-N3-propylbenzene-1,3,5-tricarboxamide
-
-
N2-acetyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
N2-[(2R,4S)-5-[[N-[[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
N2-[(2R,4S)-5-[[N-[[(3,5-dimethyl-1H-pyrazol-1-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-2,4,6-trimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
-
-
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
-
-
Nalpha-(1,3-benzodioxol-5-ylcarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
40.29% inhibition at 0.01 mg/ml
Nalpha-(1,3-benzodioxol-5-ylcarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
16.2% inhibition at 0.01 mg/ml
Nalpha-(2,4-dichlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
22.23% inhibition at 0.01 mg/ml
Nalpha-(2,4-dichlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
20.26% inhibition at 0.01 mg/ml
Nalpha-(3,4-dimethoxybenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
18.3% inhibition at 0.01 mg/ml
Nalpha-(3,5-dinitrobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
7.61% inhibition at 0.01 mg/ml
Nalpha-(3,5-dinitrobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
0.91% inhibition at 0.01 mg/ml
Nalpha-(3-chlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
25.66% inhibition at 0.01 mg/ml
Nalpha-(3-chlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
16.92% inhibition at 0.01 mg/ml
Nalpha-(tert-butoxycarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
30.06% inhibition at 0.01 mg/ml
Nalpha-(tert-butoxycarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
25.76% inhibition at 0.01 mg/ml
Nalpha-benzoyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
11.2% inhibition at 0.01 mg/ml
NB-216
-
-
NB-544
-
-
OM00-3
-
Glu-Leu-Asp-Leu*Ala-Val-Glu-Phe, the asterisk denotes a hydxoxyethelene transition state isostere
OM99-2
-
Glu-Val-Asn-Leu*Ala-Ala-Glu-Phe, the asterisk denotes a hydxoxyethelene transition state isostere
OM99-2
-
pH dependence of BACE1 activity in solution with and without OM99-2 shown, surface representation in the active site cleft with superimposed OM99-2 at pH 5 shown by crystallization, active and inactive structures determined
OM99-2
-
complete inhibition at 0.0001 nM
OM99-2
-
i.e. Glu-Val-Asn-(S)-CH(OH)CH2-Leu-Ala-Glu-Phe-OH
OM99-2
-
i.e. Glu-Val-Asn-[(2R,4S,5S)-5-amino-4-hydroxy-2,7-dimethyl-octanoyl]-Ala-Glu-Phe-OH, potent inhibitor
pepstatin A
-
less potent inhibitor
phlorofurofucoeckol-A
-
significant BACE1 inhibition in a dose-dependent manner
Phloroglucinol
-
significant BACE1 inhibition in a dose-dependent manner
pyridin-3-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
pyridin-4-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
quercetin
-
significant BACE1 inhibition in a dose-dependent manner
rebaichromone
-
-
reticulon 3
-
-
-
reticulon 4
-
-
-
rosmarinic acid
-
isolated from methanolic extracts of Perilla frutescens
S-(tetrahydrofuran-3-yl) [(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]carbamothioate
-
-
tert-butyl 5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-methyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl [(2S)-1-[[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamate
-
50.53% inhibition at 0.01 mg/ml
trans-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
-
triphloroethol A
-
significant BACE1 inhibition in a dose-dependent manner
Z-DEVD-FMK
-
caspase-3 inhibitor Z-DEVD-FMK reduces BACE1 mRNA and protein levels, and inhibits its protease activity, thereby decreasing the amount of amyloid precursor protein C99 and beta-amyloid in ischemic brains
[(1R,2R,4R,5S,6S)-2-hydroxy-7-sulfo-4-[(sulfooxy)methyl]-3-oxa-7-azabicyclo[4.1.0]hept-5-yl 2-O-sulfo-beta-D-glucopyranosiduronic acid]n
-
IC50: 0.000031 mg/ml
[(2R,4S,5S)-5-[N-(3,4-dimethoxy)benzoyl-L-phenylalanylamido]-4-hydroxy-2,7-dimethyloctan] N'-isobutyl amide
-
14.66% inhibition at 0.01 mg/ml
[2-(acetylamino)-2-deoxy-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.00041 mg/ml
[2-(acetylamino)-2-deoxy-4-O-beta-D-glucopyranuronosyl-6-O-sulfo-beta-D-glucopyranose]n
-
IC50: 0.000091 mg/ml
[2-(acetylamino)-2-deoxy-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000031 mg/ml
[2-amino-2-deoxy-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000159 mg/ml
[2-deoxy-2-(butanoylamino)-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000055 mg/ml
[2-deoxy-2-(propanoylamino)-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000053 mg/ml
[2-deoxy-2-(sulfoamino)-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.0001 mg/ml
[2-deoxy-4-O-(2,3-di-O-sulfo-beta-D-glucopyranuronosyl)-6-O-sulfo-2-(sulfoamino)-beta-D-glucopyranose]n
-
IC50: 0.000053 mg/ml
[2-deoxy-6-O-sulfo-2-(sulfoamino)-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
porcine mucosal intestinal heparin, IC50: 0.000028 mg/ml
[3-([1-benzyl-2-hydroxy-3-[(1-methylethyl)amino]propyl]carbamoyl)-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
[3-([1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyl]carbamoyl)-5-[[(2,5-dimethyl-1,3-oxazol-4-yl)methyl]carbamoyl]phenyl]methylsulfamic acid
-
-
[3-[(1-[1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl]-3-methylbutyl)carbamoyl]-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
methyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
additional information
-
strategies for inhibitor design
-
additional information
-
overview on first generation inhibitors, inhibitor design
-
additional information
-
murine BACE1 in amyloid precursor protein transgenic mouse models should exhibit similar pharmacological and enzymatic profiles to those of human BACE1 and should thus be useful in the development of BACE inhibitors for the treatment of Alzheimer's disease
-
additional information
-
structures of BACE1 inhibitors containing a tetrazole ring at the P4 position indicated, inhibitory activities summarized
-
additional information
-
design of selective non-peptidic small molecule inhibitors of beta-secretase BACE1, substitution of a thiophene ring for the key pyrrole nucleus in a series of substituted acylguanidines performed
-
additional information
-
isophthalic-type aromatic residues at the P2 position and an HMC isostere at the P1 position used as lead compounds for generation of novel inhibitors against beta-secretase BACE1, development of novel inhibitors against beta-secretase BACE1 studied, novel nonpeptidic and small-sized BACE1 inhibitors possessing a 2,6-pyridinedicarboxylic, chelidamic or chelidonic residue at the P2 position described, inhibitory activities summarized
-
additional information
-
membrane excitability normalized by BACE1 inhibitor GL189 in Alzheimer disease patients reveals association between BACE1 and regulatory role on voltage-gated sodium channel by cleavage of beta2 subunit
-
additional information
-
in presenilin 1 mutants I143T or G384A, acceleration of apoptosis, elevation of caspase 3/7 activity, and significant increases in caspase-4, caspase-8, and caspase-9 activities during apoptosis are observed,. Treatment with a beta-secretase inhibitor significantly attenuates the effects of the presenilin 1 mutants on caspase 3/7 activation and recovers cell viability
-
additional information
-
in presenilin 1 mutants I143T or G384A after treatment with apoptosis-inducing agents, increasing levels of p53 protein are enhanced. Treatment with a beta-secretase inhibitor counteracts the increases in the p53 protein levels
-
additional information
-
cholesterol depletion within the cellular context inhibits both beta-secretase and gamma-secretase additively and independently from each other. The parallel and additive inhibition may indicate an intrinsic cross-talk between Alzheimer disease-related amyloid precursor protein processing, amyloid precursor protein function, and lipid biology; cyclodextrin does not affect the protein levels of BACE I
-
additional information
-
gamma-secretase affects BACE1 expression and induces an increase in protein levels in Alzheimer's disease
-
additional information
-
caspase-3 inhibitor Z-DEVD-FMK reduces BACE1 mRNA and protein levels, and inhibits its protease activity, thereby decreasing the amount of amyloid precursor protein C99 and amyloid beta in ischemic brains. Caspase-3 inhibition attenuates ischemia-induced amyloid beta-formation by reducing BACE1 production and activity
-
additional information
-
CP-681301 treatment leads to significant reduction of BACE1 mRNA and protein
-
additional information
-
in wild-type as well as transgenic Tg2576 mice, no effect on BACE-1 activity can be observed by standardized Ginkgo biloba extract EGb761, a flavonol fraction or a terpenelactone fraction from Ginkgo biloba leaf; neither standardized Ginkgo biloba extract EGb761, a flavonol fraction or a terpenelactone fraction from Ginkgo biloba leaf affect BACE-1 activity in vitro or in Neuro-2a cells
-
additional information
-
not inhibited by xanthoxol
-
additional information
-
presence of a flavanone moiety in the amentoflavone biflavonoid is advantageous for inhibitory activity
-
additional information
-
a pyrrolidinyl side group at the P3' and P4' positions of the inhibitors are favored for strong inhibition and a small aromatic group at the P4 position is also essential to the potency
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
4-hydroxynonenal
induction of BACE1 expression under oxidative stress determined
bovine lung heparin
-
0.0001 mg/ml increases BACE1 activity by 1600%
-
etazolate
-
i.e. 1-ethyl-4-(N'-isopropylidene-hydrazino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester, stimulates alpha-secretase activity
H2O2
induction of BACE1 expression under oxidative stress determined
heparan sulfate
-
0.0001 mg/ml increases BACE1 activity by 900%
heparin
-
stimulates the partially active BACE1 zymogen. The activation is mediated by high-affinity binding of heparin to the pro-domain
mucosal heparin
-
0.0001 mg/ml increases BACE1 activity by 900%, heparin tetrasaccharide inhibits stimulation of proBACE1 by full-length mucosal heparin at concentrations of greater than 0.0005 mg/ml
-
poly-D-glutamic acid
-
0.0001 mg/ml increases BACE1 activity by 170%
-
polysialic acid
-
0.0001 mg/ml increases BACE1 activity by 160%
sphingoisine-1-phosphate
-
treatment by sphingosine kinase inhibitor, RNA interference knockdown of sphingosine kinase, or overexpression of sphingosine 1-phosphate degrading enzymes decrease BACE1 activity, which reduces amyloid beta production. Sphingosine-1-phosphate specifically binds to full-length BACE1 and increases its proteolytic activity, suggesting that cellular sphingosine 1-phosphate directly modulates BACE1 activity
sphingosine 1-phosphate
-
treatment by sphingosine kinase inhibitor, RNA interference knockdown of sphingosine kinase, or overexpression of sphingosine 1-phosphate degrading enzymes decrease BACE1 activity, which reduces amyloid beta production. Sphingosine-1-phosphate specifically binds to full-length BACE1 and increases its proteolytic activity, suggesting that cellular sphingosine 1-phosphate directly modulates BACE1 activity
heparin
-
heparin can increase the enzyme activity of the partially active zymogen proBACE1
additional information
-
upon exposure to various cell stressors including amyloid-beta 1-42, expression of BACE1-antisense transcript becomes elevated leading to increased BACE1 mRNA stability. BACE1 expression by BACE1-antisense transcript does not occur only at the mRNA but also at the protein level. BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease-associated pathophysiology.
-
additional information
-
BACE1 is increased by oxidative stress, oxidative stress fails to induce BACE1 expression in presenilin-1 (gamma-secretase)-deficient cells and in normal cells treated with gamma-secretase inhibitors, 4-hydroxy-2,3-nonenal enhances the expression of BACE1 in a gamma-secretase-dependent manner
-
additional information
-
in cells overexpressing amyloid precursor protein, thiamine deficiency promotes maturation of beta-site amyloid precursor protein cleaving enzyme 1, BACE1 and increases beta-secretase activity which results in elevated levels of beta-amyloid as well as beta-secretase cleaved C-terminal fragment. An inhibitor of beta-secretase efficiently reduces thiamine deficiency-induced up-regulation of amyloid beta and beta-secretase cleaved fragment. Thiamine supplementation reverses the thiamine deficiency-induced alterations. Thiamine deficiency treatment causes a significant accumulation of reactive oxygen species. Antioxidants suppress reactive oxygen species production and maturation of BACE1, as well as thiamine deficiency-induced amyloid beta accumulation. Exogenous amyloid beta1-40 enhances thiamine deficiency-induced production of reactive oxygen species
-
additional information
-
thiamine deficiency causes amyloid beta accumulation in the brain, which is reversed by thiamine supplementation. Thiamine deficiency can promote beta-secretase activity, and the accumulation of amyloid beta subsequently exacerbates thiamine deficiency-induced oxidative stress
-
additional information
-
overexpression of peptide p25 leads to increased levels of BACE1 mRNA and protein in vitro and in vivo
-
additional information
-
heparin disaccharide does not stimulate proBACE1 activity at a concentration of 0.00001-0.1 mg/ml
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0045
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)
-
pro-memapsin 2
0.055
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR
-
-
0.0054
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
-
pro-memapsin 2
1.71
EEISEVNLDAEFRG
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
0.00191
M-2420 peptide
-
apparent value, free enzyme, pH and temperature not specified in the publication
12.8
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2
-
-
4.07
SEVNLDAEFR
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
0.00832
M-2420 peptide
-
apparent value, immobilized enzyme reactor enzyme, pH and temperature not specified in the publication
additional information
additional information
-
ratio kcat/Km for substrates SEVKMDAEFR and EEISEVKMDAEFRG is 53.3 per M and s and 95 per M and s, respectively
-
additional information
additional information
-
significant individual variations of Vmax and Km values determined, Vmax values found to be significantly increased in Alzheimer disease cases
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.155
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR
Homo sapiens
-
-
17.6
EEISEVNLDAEFRG
Homo sapiens
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
0.000068
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2
Homo sapiens
-
-
10.7
SEVNLDAEFR
Homo sapiens
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
3.298
casein-FITC
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
163625
6.222
M-2420 peptide
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
41333
1.286
panvera peptide
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
163626
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000008
(13S)-15-amino-10,13-dicyclohexyl-19-fluoro-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
pH and temperature not specified in the publication
0.000012
(13S)-15-amino-10,13-dicyclohexyl-19-methoxy-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
pH and temperature not specified in the publication
0.000005
(13S)-15-amino-10,13-dicyclohexyl-2-oxa-10,14,16,19-tetraazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
pH and temperature not specified in the publication
0.000005
(14S)-16-amino-10,14-dicyclohexyl-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000008
(14S)-16-amino-10-cyclohexyl-14-(propan-2-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000022
(14S)-16-amino-14-(propan-2-yl)-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000017
(14S)-16-amino-14-cyclohexyl-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000186
(15R)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
pH and temperature not specified in the publication
0.000031
(15S)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
pH and temperature not specified in the publication
0.000014
(7S,12Z)-N-[(2S,4R)-2-hydroxy-4-methyl-5-[[(1S)-2-methyl-1-(phenylcarbamoyl)propyl]amino]-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadec-12-ene-7-carboxamide
-
-
0.000295
11-oxo-N-(pyridin-4-yl)-10,11-dihydro-5H-dibenzo[b,e][1,4]-diazepine-3-carboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.00006
16-amino-11-cyclohexyl-2-oxa-11,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-12-one
-
pH and temperature not specified in the publication
0.000025
2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-6-methoxy-1Hbenzo[d]imidazole
-
pH 4.5, 25C
0.000309
3-(3H-imidazo[4,5-c]pyridin-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000293
3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000348
3-(5-(pyridin-4-yl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]-diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000244
3-(6-fluoro-1H-benzo[d]imidazol-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.0009
3-[2-amino-6-(phenylcarbonyl)quinazolin-3(4H)-yl]-N-cyclohexyl-N-methylpropanamide
-
-
0.000011
4-(2-amino-6-phenoxyquinazolin-3(4H)-yl)-N,4-dicyclohexyl-N-methylbutanamide
-
-
0.0113
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid methyl ester
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.000017
6-fluoro-2-(3-(7-fluoroimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo[d]imidazole
-
pH 4.5, 25C
0.000034
6-fluoro-2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo-[d]imidazole
-
pH 4.5, 25C
0.00002
cis-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
pH and temperature not specified in the publication
0.0018
GRL-8234
-
i.e. inhibitor 24, memapsin 2 enzyme inhibition assay
0.062
luteolin
-
-
0.000211
N-(4-fluorophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e]-[1,4]diazepine-3-carboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.0000018
N-[(1S,2R)-1-benzyl-2-hydroxy-3-[(3-ethoxybenzyl)amino]propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
pH 4.5, 37C
0.00021
N-[(1S,2R,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00007
N-[(1S,2S,4R)-2-azido-4-((S)-1-benzylcarbamoyl-2-methyl-propylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000031
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-(2-methoxy-ethoxy)-butyl]-5-(methanesulfonyl-methylamino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.000003
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-propyloxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000021
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-ethyloxy-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00014
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-2-amino-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000033
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-allyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00002
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-benzyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000013
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-cyclopropylmethoxy-1-(3,5-difluorophenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonylmethyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00013
N-[(1S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxybutyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenylethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00001
N-[(2S,3S)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)amino]benzene-1,3-dicarboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000001
N-[(2S,3S,5R)-6-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-1-(3,5-difluorophenoxy)-3-hydroxy-5-methoxy-6-oxohexan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
Ki less than 0.000001 mM, pH and temperature not specified in the publication
0.0000011
N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(2-methylpropyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-5-[methyl(methylsulfonyl)amino]-N'-(1-phenylethyl)benzene-1,3-dicarboxamide
-
-
0.00000012
N2-[(2R,4S)-5-[[N-[[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
0.0000003
N2-[(2R,4S)-5-[[N-[[(3,5-dimethyl-1H-pyrazol-1-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
0.0000003
OM00-3
-
-
0.000001
OM99-2
-
memapsin 2
0.0000016
OM99-2
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.0000018
OM99-2
-
-
0.0000098
OM99-2
-
pro-memapsin 2
0.039
rosmarinic acid
-
-
0.001
trans-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
Ki above 0.001 mM, pH and temperature not specified in the publication
0.000425
[3-([1-benzyl-2-hydroxy-3-[(1-methylethyl)amino]propyl]carbamoyl)-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
0.000552
[3-([1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyl]carbamoyl)-5-[[(2,5-dimethyl-1,3-oxazol-4-yl)methyl]carbamoyl]phenyl]methylsulfamic acid
-
-
0.000916
[3-[(1-[1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl]-3-methylbutyl)carbamoyl]-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.2197
(+)-byakangelicin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.1049
(+)-byakangelicol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.3592
(+)-oxypeucedanin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.00311
(-)-gallocatechin gallate
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
0.1275
(-)-gallocatechin gallate
Homo sapiens
-
enzyme reactor-immobilized enzyme, pH and temperature not specified in the publication
0.00017
(1R,3S)-3-[(1S)-1-(acetylamino)-2-methylpropyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
(1R,3S)-3-[(1S)-1-(acetylamino)-2-methylpropyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0015
(1R,3S)-3-[1-(acetylamino)cyclopentyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0027
(1R,3S)-3-[1-(acetylamino)cyclopentyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0038
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0042
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00037
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0037
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000025
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopiperidin-1-yl)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00014
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopiperidin-1-yl)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopyrrolidin-1-yl)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00096
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopyrrolidin-1-yl)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00058
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(propanoylamino)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0037
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(propanoylamino)propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-[methyl(propanoyl)amino]propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-[methyl(propanoyl)amino]propan-2-yl]cyclohexanecarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000511
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[(1-benzylpiperidin-4-yl)amino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.000222
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)-amino]-N'-[(R)-1-(4-fluorophenyl)ethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.000567
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.00015
(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]butanamide
Homo sapiens
-
-
0.00059
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide
Homo sapiens
-
-
0.00025
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]-4-hydroxy-2-methylbutanamide
Homo sapiens
-
-
0.000008
(2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0056
(2S,5S,8S,11S,14S)-14-amino-5-benzyl-8-(cyclohexylmethyl)-16-(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-2-hydroxy-11-(1-methylethyl)-4,7,10,13,16-pentaoxo-N-[3-(2H-tetrazol-5-yl)phenyl]-3,6,9,12-tetraazahexadecan-1-amide
Homo sapiens
-
i.e. KMI-574, used as a substrate transition-state mimic
0.000022
(3S,14R,16S)-16-[(1R)-1-hydroxy-2-([3-(1-methylethyl)benzyl]amino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
Homo sapiens
-
-
0.000002
(3S,14R,16S)-16-[(1S)-2-[[(1R)-3,3-dimethyl-7-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
Homo sapiens
-
-
0.000001
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(2-oxopyrrolidin-1-yl)-11,16-dioxa-3-azatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(methoxymethyl)-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000017
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000083
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]ethyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
(4S)-4-[(1R)-1-hydroxy-2-([2-[3-(propan-2-yl)phenyl]propan-2-yl]amino)ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000292
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00006
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000042
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000027
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11-oxa-3,16,18-triazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2,2,2-trifluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000177
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-fluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000668
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-methoxyethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000067
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclobutyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclopentyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
(5S)-2-amino-5-(2',4'-difluorobiphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00001
(5S)-2-amino-5-[3-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.039
(6R)-2,6-anhydro-5-O-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-[2-[(2R)-2-hydroxypropyl]-7-methoxy-5-methyl-4-oxo-4H-chromen-8-yl]-L-glucitol
Homo sapiens
-
pH 4.0, 25C
0.0205
(6R)-2,6-anhydro-6-[7-methoxy-5-methyl-4-oxo-2-[(1E)-prop-1-en-1-yl]-4H-chromen-8-yl]-L-glucitol
Homo sapiens
-
pH 4.0, 25C
0.000011
(R)-3-(2-amino-6-(3-chloropyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000016
(R)-3-(2-amino-6-(3-methylpyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0059
1-(2-chlorobenzyl)-4-(4-(dibenzo[b,d]furan-1-yl)benzyl)-1H-imidazol-2-amine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0056
1-(4-fluorobenzyl)-4-((30,50-dimethoxybiphenyl-4-yl)methyl)-1H-imidazol-2-amine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0447
1-[(3-benzoylamino-phenylcarbamoyl)-methyl]-3-carbamoyl-pyridiniumchloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.003
1-[(E)-[(4-methylquinazolin-2-yl)amino][(phenylcarbamoyl)amino]methylidene]-3-phenylurea
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.012
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.001
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.0037
1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.0022
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.013
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.00035
2,3-dihydro-6-methylginkgetin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00075
2,3-dihydroamentoflavone
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0606
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
Homo sapiens
-
prenylated flavone from the stem bark of Morus lhou, pH not specified in the publication, temperature not specified in the publication
0.000026
2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-6-methoxy-1Hbenzo[d]imidazole
Homo sapiens
-
pH 4.5, 25C
0.00516
2-amino-3-ethyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00077
2-amino-3-methyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00117
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.0022
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00048
2-amino-3-methyl-5-(pyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00387
2-amino-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-5-[3-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00201
2-amino-3-methyl-5-phenyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00083
2-amino-3-methyl-5-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00613
2-amino-3-methyl-5-[2-(propan-2-yl)pyridin-4-yl]-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.08719
2-amino-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00054
2-amino-5-(1,3-benzodioxol-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
2-amino-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00113
2-amino-5-(2,3-dihydro-1-benzofuran-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0236
2-amino-5-(2,6-diethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.0241
2-amino-5-(2,6-dimethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00102
2-amino-5-(2-ethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00959
2-amino-5-(3,4-dimethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00555
2-amino-5-(3-butoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00042
2-amino-5-(3-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00253
2-amino-5-(3-ethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00629
2-amino-5-(3-methoxy-4-methylphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00068
2-amino-5-(3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00119
2-amino-5-(3-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00184
2-amino-5-(4-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00433
2-amino-5-(4-ethyl-3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00096
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-(6-methylbiphenyl-3-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00079
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00159
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00172
2-amino-5-(4-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00014
2-amino-5-(biphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00417
2-amino-5-(biphenyl-3-yl)-5-(3,4-dimethoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00017
2-amino-5-(biphenyl-3-yl)-5-(3-butoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00056
2-amino-5-(biphenyl-3-yl)-5-(3-chloro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00096
2-amino-5-(biphenyl-3-yl)-5-(3-cyclopentyl-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0006
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-propoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00052
2-amino-5-(biphenyl-3-yl)-5-(3-fluoro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00078
2-amino-5-(biphenyl-3-yl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0003
2-amino-5-(biphenyl-3-yl)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00184
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(propan-2-yloxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00504
2-amino-5-[2-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00078
2-amino-5-[3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.00078
2-amino-5-[3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00251
2-amino-5-[3-(2-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00248
2-amino-5-[3-(6-fluoropyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00599
2-amino-5-[3-(6-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00126
2-amino-5-[3-fluoro-5-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00184
2-amino-5-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00969
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0028
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0345
2-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-2-oxoethyl [(4,6-diphenylpyrimidin-2-yl)sulfanyl]acetate
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.02
2-[(3-cyano-4,6-diphenylpyridin-2-yl)sulfanyl]-N-(3-nitrophenyl)acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.021
2-[(4-methyl-5-[2-[(4-methylphenyl)amino]-2-oxoethyl]-4H-1,2,4-triazol-3-yl)sulfanyl]-N-(4-phenyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.0102
2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]-N-(2-fluorophenyl)acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.096
2-[[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]carbamoyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridin-4-yl methanesulfonate
Homo sapiens
-
i.e. KMI-1036, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
0.001
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]ethanol
Homo sapiens
-
pH and temperature not specified in the publication
0.118
2-[[3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl]sulfanyl]-N-(tricyclo[3.3.1.1(3,7)]dec-1-yl)acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.05
2-[[3-cyano-6-(4-fluorophenyl)-4-phenylpyridin-2-yl]sulfanyl]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.05
2-[[4-(4-chlorophenyl)-3-cyano-6-(4-methoxyphenyl)pyridin-2-yl]sulfanyl]-N-(naphthalen-2-yl)-N-phenylacetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.1
2-[[4-benzyl-5-(1H-indol-3-ylmethyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)ethanone
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.00005
3-(6-(2-acetylphenyl)-2-aminoquinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.1
3-(benzylsulfanyl)-6-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6,7-dihydro[1,2,4]triazino[5,6-d][3,1]benzoxazepine
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.000004
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(3,3,3-trifluoropropanoyl)-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000022
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(methoxyacetyl)-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-3-ylacetyl)-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000011
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-4-ylacetyl)-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
3-(butylsulfonyl)-N2-(3-cyanopropanoyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
3-(butylsulfonyl)-N2-(cyclopropylcarbonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00367
3-(cyclohexylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000484
3-(dibutylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00109
3-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000596
3-(heptan-4-ylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0302
3-carbamoyl-1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.0019
3-carbamoyl-1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.000005
3-chloro-N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.004
3-phenethylcarbamoyl-1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 37C
0.0000012
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
0.0002 mM, complete inhibition, IC50: 1.2 nM
0.0012
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
i.e. KMI-684, used as a substrate transition-state mimic
0.0000039
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
0.0002 mM, 98.1% inhibition, IC50: 3.9 nM
0.0039
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
i.e. KMI-429, used as a substrate transition-state mimic
0.0000082
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
0.002 mM, 87.1% inhibition, IC50: 8.2 nM
0.0082
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
Homo sapiens
-
i.e. KMI-420, used as a substrate transition-state mimic
0.0000048
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
Homo sapiens
-
0.0002 mM, 98.1% inhibition, IC50: 4.8 nM
0.0048
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
Homo sapiens
-
i.e. KMI-570, used as a substrate transition-state mimic
0.0000066
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
Homo sapiens
-
0.0002 mM, 94.2% inhibition, IC50: 6.6 nM
0.0000064
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
Homo sapiens
-
0.0002 mM, 97.2% inhibition, IC50: 6.4 nM
0.0000048
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-(1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl)leucinamide
Homo sapiens
-
-
0.0000012
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-[1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl]leucinamide
Homo sapiens
-
-
0.00012
3-[5-[(1R)-1-amino-1-methyl-2-phenylethyl]-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.0000056
3-[[(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)carbonyl]amino]alanyl-L-valyl-N-[(1S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]phenylalaninamide
Homo sapiens
-
-
0.00047
3-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]propan-1-ol
Homo sapiens
-
pH and temperature not specified in the publication
0.0071
4-(4-[1-[(6-aminopyridin-2-yl)methyl]-5-(2-chlorophenyl)-1H-pyrrol-2-yl]phenoxy)butanenitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.00011
4-(cyclohexylamino)-1-(4-fluorobenzyl)-8-[(2'-methylbiphenyl-4-yl)methyl]-1,3,8-triazaspiro[4.5]dec-3-en-2-one
Homo sapiens
-
-
0.00795
4-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.09
4-bromo-N-[(4-bromophenyl)sulfonyl]-N-[1-(3,4-dichlorobenzyl)-1H-pyrazol-4-yl]benzenesulfonamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.0018
4-[1-(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]ethyl]-1-methyl-1H-imidazol-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.00047
4-[2-(2-methoxy-5-nitrophenyl)-1-(4-methoxyphenyl)ethyl]-1-methyl-1H-imidazol-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.000063
4-[4-fluoro-5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.0032
4-[5-methoxy-2-(2-methoxy-5-nitrophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.00035
4-[5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.008
4-[8-benzyl-4-(cyclohexylamino)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-1-yl]benzamide
Homo sapiens
-
-
0.00232
5-[2-amino-4-(4-methoxy-3-methylphenyl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]biphenyl-2-carbonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.00055
5-[2-amino-4-(biphenyl-3-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]-2-methoxybenzonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.64
6,7-furano-5,8a-dimethoxy hydrocoumaric acid methyl ester
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.1856
6,7-furano-5-prenyloxy hydrocoumaric acid
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0305
6,7-furano-5-prenyloxy hydrocoumaric acid methyl ester
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.2033
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0162
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid methyl ester
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0018
6-fluoro-2-(3-(7-fluoroimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo[d]imidazole
Homo sapiens
-
pH 4.5, 25C
0.000035
6-fluoro-2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo-[d]imidazole
Homo sapiens
-
pH 4.5, 25C
0.00859
7-phloroethol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0383
8,8-diphenyl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine
Homo sapiens
-
temperature not specified in the publication, in 20 mM Tris-HCl, pH 7.4
0.0046
8-(biphenyl-4-ylmethyl)-4-(cyclohexylamino)-1-(4-fluorobenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
Homo sapiens
-
-
0.011
8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
Homo sapiens
-
-
0.039
aloeresin D
Rattus norvegicus
-
-
0.0269
benzyl 1-(3-acetoxypropyl)-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0391
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(dimethylamino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0282
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(isopropyl(methyl)amino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0155
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-ethoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.009
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0161
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4-dimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0152
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-methoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0284
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(2-morpholino-2-oxoethyl)-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0149
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0214
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-phenyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0081
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0095
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.011
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-isopropyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
benzyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000098
beta-secretase inhibitor IV
Homo sapiens
-
using SEVNLDAEFRHDSGYEK-biotin as substrate, in 50 mM sodium acetate, pH 4.5, containing 0.25 mg/ml bovine serum albumin, temperature not specified in the publication
0.0000124
beta-secretase inhibitor IV
Homo sapiens
-
using SEVKMDAEFRHDSGYEK-biotin as substrate, in 50 mM sodium acetate, pH 4.5, containing 0.25 mg/ml bovine serum albumin, temperature not specified in the publication
0.0205
C-2'-decoumaroyl-aloeresin G
Rattus norvegicus
-
-
0.00221
dieckol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.00535
dioxinodehydroeckol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0122
eckol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.000603
EVD(statine)VAEF
Mus musculus
-
IC50: 0.000603 mM
0.000651
EVD(statine)VAEF
Homo sapiens
-
IC50: 0.000651 mM
0.00045
EVE(statine)VAEF
Homo sapiens
-
IC50: 0.00045 mM
0.000452
EVE(statine)VAEF
Mus musculus
-
IC50: 0.000452 mM
0.004673
EVG(statine)VAEF
Mus musculus
-
IC50: 0.004673 mM
0.005319
EVG(statine)VAEF
Homo sapiens
-
IC50: 0.005319 mM
0.000251
EVL(statine)VAEF
Mus musculus
-
IC50: 0.000251 mM
0.000265
EVL(statine)VAEF
Homo sapiens
-
IC50: 0.000265 mM
0.0000014
EVNLAAEF
Mus musculus
-
Leu in the transition state isostere, i.e. OM99-2, IC50: 0.0000014 mM
0.0000016
EVNLAAEF
Homo sapiens
-
Leu in the transition state isostere, i.e. OM99-2, IC50: 0.0000016 mM
0.0066
EVW(statine)VAEF
Mus musculus
-
IC50: 0.0066 mM
0.00754
EVW(statine)VAEF
Homo sapiens
-
IC50: 0.00754 mM
0.000118
EVY(statine)VAEF
Homo sapiens
-
IC50: 0.000118 mM
0.000126
EVY(statine)VAEF
Mus musculus
-
IC50: 0.000126 mM
0.001
GRL-8234
Homo sapiens
-
i.e. inhibitor 24, in Chinese hamster ovary cells
0.0918
imperatorin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.2442
isoimperatorin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0312
isopropyl 2-(3-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0328
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-methyl-5-((R)-1-phenylethylcarbamoyl)pyridin-1(4H)-yl) acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0296
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0232
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenyl butan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0261
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0266
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0264
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0293
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0271
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0293
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.0331
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.041
KTEETSEVN(statine)VAEF
Homo sapiens
-
i.e. P10-P40 StatVal, dose-dependent inhibition shown, cleavage determined by fluoresence assay
0.0034
kuwanon
Homo sapiens
-
prenylated flavone from the stem bark of Morus lhou, pH not specified in the publication, temperature not specified in the publication
0.0053
kuwanon A
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000012
L-alpha-glutamyl-L-leucyl-N-[(2S,5S,8S,14R)-2-carboxy-5-(carboxymethoxy)-13-hydroxy-11,16-dimethyl-13-oxido-4,7,10-trioxo-1-phenyl-8-(propan-2-yl)-3,6,9-triaza-13-lambda5-phosphaheptadecan-14-yl]-L-alpha-asparagine
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
luteolin
Perilla frutescens
-
non-competitive inhibition
0.0002
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-(statine)-Val-Ala-Glu-Phe-OH
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.00012
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.00014
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[statine(3S,4S)]-Val-Ala-Glu-Phe-OH
Homo sapiens
-
enzyme reactor-immobilized enzyme, pH and temperature not specified in the publication; free enzyme, pH and temperature not specified in the publication
0.0594
morusin
Homo sapiens
-
prenylated flavone from the stem bark of Morus lhou, pH not specified in the publication, temperature not specified in the publication
0.000005
N'-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-5-methyl-N,N-dipropylbenzene-1,3-dicarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00031
N'-[(2S,3R)-3-hydroxy-4-[(3-iodobenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
N'-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0122
N,N'-bis(3-cyano-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl)-2,2,3,3,4,4,5,5-octafluorohexanediamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.000015
N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00046
N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
Homo sapiens
-
enzyme reactor-immobilized enzyme, pH and temperature not specified in the publication
0.024
N-(2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl)methanesulfonamide
Homo sapiens
-
-
0.000076
N-(2-methylpropyl)-N2-([17-[(methylsulfonyl)(propyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]icosa-1(19),6(20),7,9,15,17-hexaen-4-yl]methyl)-L-norleucinamide
Homo sapiens
-
-
0.0028
N-(4-([4-(cyclohexylamino)-1-(3-fluorophenyl)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-8-yl]methyl)phenyl)acetamide
Homo sapiens
-
-
0.015
N-(5-([6-(4-(N,N-dimethyl)aminophenyl)pyrimidin-4-yl]amino)-2-methylphenyl)-N-methylmethanesulfonamide
Homo sapiens
-
-
0.021
N-(5-[[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidin-4-yl]amino]-2-methylphenyl)-N-methylmethanesulfonamide
Homo sapiens
-
-
0.00231
N-(tert-butoxycarbonyl)-L-leucyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000027
N-acetyl-beta-alanyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.004
N-acetyl-L-alanyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00012
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000053
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00037
N-acetyl-L-valyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0116
N-benzyloxycarbonyl-Val-Leu-leucinal
Rattus norvegicus
-
-
0.000005
N-[(1R,2S)-1-benzyl-2-hydroxy-3-[[3-(trifluoromethyl)benzyl]amino]propyl]-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5-(ethylamino)-2-fluorobenzamide
Homo sapiens
-
-
0.000002
N-[(1S)-1-[(butylsulfonyl)methyl]-2-([1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]amino)-2-oxoethyl]benzamide
Homo sapiens
-
-
0.36
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-1,4-dihydropyridine-2-carboxamide
Homo sapiens
-
i.e. KMI-1030, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
0.05
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-4H-pyran-2-carboxamide
Homo sapiens
-
i.e. KMI-1027, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
0.14
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridine-2-carboxamide
Homo sapiens
-
i.e. KMI-1023, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
0.00011
N-[(1Z)-amino(butylamino)methylidene]-2-[2-(2-chlorophenyl)-5-(4-propoxyphenyl)-1H-pyrrol-1-yl]acetamide
Homo sapiens
-
-
0.000015
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-2-methylbenzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-3-hydroxybenzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000053
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-(trifluoromethyl)benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methoxybenzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methylbenzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]pyridine-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000049
N-[(2R)-2-amino-1-benzyl-3-fluoropropyl]-2-[[(2-methylcyclopropyl)methyl]amino]-6-[methyl[(1-methylethyl)sulfonyl]amino]pyridine-4-carboxamide
Homo sapiens
-
-
0.00467
N-[(2S)-1-([(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]amino)-1-oxo-3-phenylpropan-2-yl]naphthalene-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-1H-imidazole-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-4-hydroxypyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-5-methyl-1H-pyrazole-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyrazine-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0041
N-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-3-methylbenzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.005214
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(phenylsulfonyl)propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.003785
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(piperidin-1-ylsulfonyl)propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.005015
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfamoyl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.005614
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfonyl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.004131
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(phenylsulfonyl)butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.006461
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(piperidin-1-ylsulfonyl)butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
N-[(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000616
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl-5-methyl(methylsulfonyl)amino]isophthalamide
Homo sapiens
-
pH 4.0
0.00264
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00379
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01573
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01954
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-[(5R)-5-amino-5-methyl-4,16-dioxo-14-phenyl-3-oxa-15-azatricyclo[15.3.1.17,11]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide
Homo sapiens
-
-
0.0286
N-[(Z)-[(4,6-dimethylpyrimidin-2-yl)amino][(3-nitrophenyl)amino]methylidene]-10H-phenothiazine-10-carboxamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.000005
N-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl]-5-methyl-N'-propylbenzene-1,3-dicarboxamide
Homo sapiens
-
-
0.00012
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]acetamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0028
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]acetamide
Homo sapiens
-
in 50 mM Tris (pH 7.5), at 25C
0.0000025
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-3,4-dichloro-N-phenylbenzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000038
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-4-methoxy-N-phenylbenzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000048
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(2-phenylethyl)benzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.1
N-[5-(2,3-dichlorobenzyl)-1,3-thiazol-2-yl]-4-([[4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]methyl)benzamide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM Tris (pH 7.5), at 25C
0.000004
N2-acetyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
N2-acetyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0161
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-2,4,6-trimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0162
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00807
Nalpha-(1,3-benzodioxol-5-ylcarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00424
Nalpha-(2,4-dichlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00381
Nalpha-(3,4-dimethoxybenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00693
Nalpha-benzoyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000017
NB-216
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
OM00-3
Homo sapiens
-
pH and temperature not specified in the publication
0.0000024
OM99-2
Homo sapiens
-
using SEVNLDAEFRHDSGYEK-biotin as substrate, in 50 mM sodium acetate, pH 4.5, containing 0.25 mg/ml bovine serum albumin, temperature not specified in the publication
0.0000033
OM99-2
Homo sapiens
-
using SEVKMDAEFRHDSGYEK-biotin as substrate, in 50 mM sodium acetate, pH 4.5, containing 0.25 mg/ml bovine serum albumin, temperature not specified in the publication
0.00004
OM99-2
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
0.0007
OM99-2
Homo sapiens
-
enzyme reactor-immobilized enzyme, pH and temperature not specified in the publication
0.02119
pepstatin A
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
0.482
pepstatin A
Homo sapiens
-
enzyme reactor-immobilized enzyme, pH and temperature not specified in the publication
0.00213
phlorofurofucoeckol-A
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.03647
Phloroglucinol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.000004
pyridin-3-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
pyridin-4-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.01082
quercetin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.0021
rosmarinic acid
Perilla frutescens
-
non-competitive inhibition
0.000015
S-(tetrahydrofuran-3-yl) [(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]carbamothioate
Homo sapiens
-
pH and temperature not specified in the publication
0.0304
tert-butyl 5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0319
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-methyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0246
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.01168
triphloroethol A
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.000003
methyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
additional information
additional information
Homo sapiens
-
beta-secretase inhibitors with a hydroxymethylcarbonyl (HMC) isostere used as a substrate transition-state mimic, potent BACE1 inhibitory activities of about 0.0012 mM IC50 shown, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.01
-
using Z-Val-Asn-Leu-7-amido-4-methylcoumarin as substrate
0.02
-
-
additional information
-
homogenous time-resolved fluorescence assay method
additional information
-
beta-secretase (BACE1) inhibitors isolated from the methanolic extract of Perilla frutescens characterized, specificity against beta-secretase BACE1 higher than for other enzymes such as alpha-secretase (TACE), acetylcholine esterase (AchE), chymotrypsin, and elastase
additional information
-
acetylation of BACE1 on seven lysine residues of the N-terminus shown, substitution of lysine residues shown to block ability of BACE1 to be acetylated in vivo and in vitro, lysine acetylation of BACE1 shown to be required for stabilization and for leaving the endoplasmic reticulum to move ahead into secretory pathway, model of BACE1 transient lysine acetylation/deacetylation presented
additional information
-
identification of a 24-residue peptide corresponding to the C-terminus of BACE1 that binds a single copper atom with high affinity, cytoplasmic domain of BACE1 shown to interact with dedicated copper chaperone for superoxide dismutase 1, reduced activity of superoxide dismutase 1 by overproduction of BACE1 demonstrated, activity of superoxide dismutase 1, cytosolic copper and ectodomain cleavage of amyloid precursor protein APP shown to be linked through BACE1, quaternary protein complex of BACE1 with associated factors proposed
additional information
-
overview about dysregulation of BACE1 expression and activity in normal and Alzheimer brains, comparative analyses performed on BACE1 activities and protein levels in control and Alzheimer disease brain summarized, substrate with Swedish mutation of amyloid precursor protein APP and with wild-type amyloid precursor protein APP regarded, different brain regions considered, differences between BACE1 and BACE2 summarized
additional information
-
BACE1 inhibitors generated by 9-fluorenylmethoxycarbonyl-solid-phase peptide synthesis methods, characterization of BACE1 inhibitor KMI-574, generation by replacement of acidic tetrazole ring with hydrogen bond acceptor group indicated, potent inhibitory activity in cultured cells as well as in vitro enzymatic assay shown, inhibitory activities summarized
additional information
-
generation of selective non-peptidic small molecule inhibitors of BACE1, reagents and synthetic route summarized
additional information
-
synthesis, structure and potencies of BACE1 inhibitors shown, inhibitory assays summarized, novel nonpeptidic and small-sized BACE1 inhibitors developed, design of small-sized BACE1 inhibitor 2 possessing heterocyclic ring at the P2 position shown, reagents and conditions summarized, BACE1 inhibitors possessing benzylamino-type groups at the P3 position and their BACE1 inhibitory activities summarized, BACE1 inhibitors with a 5-membered ring at the P3 position and inhibitory activities indicated, molecular surface properties shown
additional information
-
basic biology of BACE1 focusing on the regulation, structure and function reviewed, overview about dysregulation of BACE1 in Alzheimer disease, behavioral and physiological alterations of BACE1 knockout mice described, putative function of BACE1 during normal conditions summarized, relationship between key risk factors for Alzheimer disease and the pathogenic alterations in BACE1 observed in the diseased state discussed
additional information
-
synthesis, structure and potencies of memapsin 2 inhibitors shown, memapsin 2 enzyme inhibitory and cellular assays described, up to 65% reduction of plasma amyloid-beta peptide in transgenic mice indicated, ligand-binding site interactions indicated by stereoview of X-ray structure
additional information
synthesis, structure and potencies of memapsin 2 inhibitors shown, up to 65% reduction of plasma amyloid-beta peptide in transgenic mice indicated
additional information
-
dysregulation of BACE1 expression and activity measured in normal and Alzheimer brains, differences between BACE1 and BACE2 analyzed, kinetics of beta-secretase enzymatic activity in individual normal and Alzheimer brains shown, activity found to be saturable following Michaelis-Menten kinetics, increased Vmax of BACE1 in Alzheimer disease cases not found to be correlated with levels of BACE1, decreased BACE1 and BACE2 levels found to be correlated with severity of neurofibrillary pathology and synaptic loss in Alzheimer disease
additional information
-
characterization of structure and regulatory region of the beta-secretase BACE1 promoter, more repetitive elements in BACE1 than in BACE2 identified, regulatory domains of BACE1 promoter shown to be different from those of BACE2, DNA-protein interaction studies performed, BACE1-driven reporter protein expression shown to be higher than those of BACE2, operation of BACE1 through a single transcriptional control site suggested, differences to BACE2 summarized, genomic mapping of BACE1 and BACE2 on chromosome and of functional domains performed
additional information
oxidative stress measured in cytosolic fractions, antibodies and immunoblot analysis performed, RNA interference and Luciferase reporter gene assay applied, stimulation of BACE1 expression by oxidative stress determined, mechanism shown to require gamma-secretase activity involving the c-jun N-terminal kinase (JNK)/c-jun pathway, inceased BACE1 levels identified in normal cells, but not in cells lacking presenilins or amyloid precursor protein, correlation with activation of JNK and c-jun determined
additional information
-
structural features of the active form of BACE1 described, regulatory mechanism of enzymatic activity of BACE1 characterized by crystallization, conformation of the flap and subsites that promote substrate binding determined, functionally essential residues and water molecules for key role in the iterative activation of BACE1 shown, dependence of BACE1 activity on dynamics of a catalytically required aspartic acid-bound water molecule BACE1 shown, data refinement and statistics summarized
additional information
-
beta2 subunit of voltage-gated sodium channel analyzed as substrate of BACE1, increase of mRNA and protein levels of pore-forming alpha subunit of sodium channel after cleavage observed, regulation of alpha subunit of voltage-gated sodium channel mediated through BACE1, association between BACE1 and cell-surface sodium current densities shown
additional information
beta2 subunit of voltage-gated sodium channel analyzed as substrate of BACE1, increase of mRNA and protein levels of pore-forming alpha subunit of sodium channel after cleavage observed, regulation of alpha subunit of voltage-gated sodium channel mediated through BACE1, association between BACE1 and cell-surface sodium current densities shown
additional information
genetic deletion of BACE1 causes hypomyelination, elevated pain sensitivity and reduced grip strength shown in BACE1-null mice, neuregulin-1 expression increased and cleavage products and phosphorylated AKT protein kinase shown to be decreased in BACE1-null mice, neuregulin-1 cleavage by BACE1 shown, processed neuregulin-1 regulates myelination by means of phosphorylation of AKT protein kinase in myelin-forming cells
additional information
increased BACE1 activity determined in hippocampal CA1 and CA3 regions of mice tretated by combination of ovariectomy and chronic stress, condition shown to evoke an impairment of hippocampus-dependent memory, association between stressful life after menopause and Alzheimer disease-related molecules suggested, BACE1 discussed as the most sensitive molecule
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
4.5
-
activity assay at
4.5
-
pH dependence of BACE1 activity in solution shown
4.5
-
cleavage of beta2 subunit of voltage-gated sodium channel by BACE1 observed at pH 4.5 but not at pH 7
4.5
cleavage of beta2 subunit of voltage-gated sodium channel by BACE1 observed at pH 4.5 but not at pH 7
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
3.5 - 4.5
-
-
4 - 7
-
different pH conditions used for studies on crystallization of BACE1
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
25
-
activity assay at
37
-
cellular inhibition assay at
37
-
activity assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
metal homeostasis analyzed in
Manually annotated by BRENDA team
-
astrocytic BACE1 expression may be important to the development of pathology in Alzheimer's disease
Manually annotated by BRENDA team
-
membrane cholesterol significantly influences membrane beta-secretase activity in a biphasic manner, with positive correlations at higher membrane cholesterol levels, and negative correlations at lower membrane cholesterol levels. Platelets from individuals with Alzheimer's disease or mild cognitive impairment are significantly more likely to lie within the negative correlation zone than control platelets
Manually annotated by BRENDA team
-
isoform BACE1B
Manually annotated by BRENDA team
-
BACE1 is expressed exclusively in neurons but not in glial cells. BACE1 is increased in remaining neurons in Alzheimer's disease brains
Manually annotated by BRENDA team
-
; both BACE1 and human cathepsin D show poor activity towards the wild-type amyloid beta-site sequence
Manually annotated by BRENDA team
-
Alzheimer disease brain and control
Manually annotated by BRENDA team
cytosolic and nuclear extracts of mouse brain tissues
Manually annotated by BRENDA team
-
Alzheimer disease patients, endogenous processing of beta2 subunit of voltage-gated sodium channel found to be increased
Manually annotated by BRENDA team
cleavage products of BACE1 determined, sodium-current densities reduced in neuroblastoma cells and hippocampal cells of transgenic mice
Manually annotated by BRENDA team
-
; levels of gamma- and beta-secretase activities are greater in brain tissue samples from Alzheimer's disease patients compared to non-demented control subjects
Manually annotated by BRENDA team
-
; BACE1 expression is decreased in diseased brain
Manually annotated by BRENDA team
-
high expression
Manually annotated by BRENDA team
Mus musculus BalbC
-
cytosolic and nuclear extracts of mouse brain tissues
-
Manually annotated by BRENDA team
-
transient acetylation and expression of BACE1 analyzed
Manually annotated by BRENDA team
-
samples from frontal cortex of both Alzheimer's disease-affected individuals and age-matched controls. BACE1 activity shows a significant positive correlation with the amount of extractable amyloid beta-peptide, and BACE1 protein and activity are significantly increased in cases of alzheimer's disease
Manually annotated by BRENDA team
-
; development of assay for cerebrospinal fluid beta-secretase-1 activity with sensitivity down to 1 pM of recombinant enzyme. Endogenous secretase-1 enzyme appears to exist as a C-terminally truncated protein. A small cohort of human subjects displays age-dependent increase in cerebrospinal fluid beta-secretase-1 activity. In Alzheimer's disease subjects, a significant decline in age-adjusted cerebrospinal fluid beta-secretase-1 activity is observed
Manually annotated by BRENDA team
-
inhibitor drugs tested
Manually annotated by BRENDA team
-
BACE1 is significantly and time-dependently increased in the ipsilateral striatum; changes in caspase-3, amyloid beta and BACE1 levels are detected in rat striatum on different days after middle cerebral artery occlusion using immunostaining. The positive labeled cells of activated caspase-3, amyloid beta, and BACE1 are significantly and time-dependently increased in the ipsilateral striatum
Manually annotated by BRENDA team
-
immortalized mouse embryonic fibroblasts from wild-type, and presenilin-deficient PS1-/-, PS2-/-, PS1-/-/PS2-/- mice. Oxidative stress fails to induce BACE1 expression in presenilin-1 deficient cells
Manually annotated by BRENDA team
-
glioblastoma-astrocytoma cell line U373, nuclear extracts used for promoter-protein binding studies
Manually annotated by BRENDA team
-
stably expressing human BACE1 enzyme, used for inhibition assay
Manually annotated by BRENDA team
-
nuclear extracts used for promoter-protein binding studies, hypoxic cells included
Manually annotated by BRENDA team
expression of BACE1 in CA1 and C3 regions analyzed under combination of chronic stress and ovariectomy
Manually annotated by BRENDA team
-
NB, nuclear extracts used for promoter-protein binding studies
Manually annotated by BRENDA team
-
BACE1 is expressed exclusively in neurons but not in glial cells. BACE1 is increased in remaining neurons in Alzheimer's disease brains
Manually annotated by BRENDA team
-
primary culture of cortical neuron
Manually annotated by BRENDA team
-
isoforms BACE1B and BACE1C
Manually annotated by BRENDA team
-
high expression
Manually annotated by BRENDA team
-
membrane cholesterol significantly influences membrane beta-secretase activity in a biphasic manner, with positive correlations at higher membrane cholesterol levels, and negative correlations at lower membrane cholesterol levels. Pharmacological inhibition of SH-SY5Y beta-secretase activity results in increased membrane cholesterol levels
Manually annotated by BRENDA team
-
; oxidative stress fails to induce BACE1 expression in cells treated with gamma-secretase inhibitors. Oxidative stress-induced beta-secretase activity and soluble beta amyloid precursor protein levels are suppressed by gamma-secretase inhibitors
Manually annotated by BRENDA team
-
; in cells overexpressing amyloid precursor protein, thiamine deficiency promotes maturation of beta-site amyloid precursor protein cleaving enzyme 1, BACE1 and increases beta-secretase activity which results in elevated levels of beta-amyloid as well as beta-secretase cleaved C-terminal fragment. An inhibitor of beta-secretase efficiently reduces thiamine deficiency-induced up-regulation of amyloid beta and beta-secretase cleaved fragment
Manually annotated by BRENDA team
-
addition of a GPI-anchor to BACE targets the enzyme exclusively to lipid raft domains
Manually annotated by BRENDA team
-
U937, nuclear extracts used for promoter-protein binding studies
Manually annotated by BRENDA team
additional information
-
methanolic extracts of Perilla frutescens
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
close interaction between BACE and low density lipoprotein receptor-related protein on the cell surface
Manually annotated by BRENDA team
-
beta-secretase is a type 1 transmembrane protein present at the cell surface
Manually annotated by BRENDA team
-
isoforms BACE1B, BACE1C, both without beta-secretase activity
Manually annotated by BRENDA team
-
lysine acetylation of maturating BACE1 protein
Manually annotated by BRENDA team
-
BACE1, minor presence
Manually annotated by BRENDA team
-
cycling of BACE1 between cell surface and the endosomal system, activation during cellular trafficking
Manually annotated by BRENDA team
-
cycling of BACE1 between the cell surface and the endosomal system, activation of BACE1 interconvertible during cellular trafficking
Manually annotated by BRENDA team
-
post-Golgi membranes, isoforms BACE1A, BACE2
Manually annotated by BRENDA team
-
largely late Golgi, BACE1
Manually annotated by BRENDA team
-
lysine deacetylation, mature BACE1 protein
Manually annotated by BRENDA team
-
BACE1 is a transmembrane aspartyl protease with a lumenal active site
Manually annotated by BRENDA team
PDB
SCOP
CATH
ORGANISM
UNIPROT